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Drug nanoparticles are a promising solution to the challenging issues of low dissolution rates 
and erratic bioavailability due to their greater surface area/volume ratio resulting in 
improvement in dissolution rate and bioavailability. The central purpose of the study carried 
on this thesis was to prepare, stabilize and isolate nanoparticles of poorly water-soluble active 
pharmaceutical ingredients (APIs) into a dried form with the help of clay carrier particles. 
Isolation of nanoparticles from suspension into the dried state is crucial to avoid the problems 
of aggregation and Ostwald ripening. In this study nanoparticles (NPs) of four poorly water-
soluble active pharmaceutical ingredients (APIs) (valsartan (Val), clozapine (CLO), curcumin 
(CUR) and carbamazepine (CBMZ) with zeta potentials -42.5±1.4, -28.5 ±2.5, -33±1.5 and -
13±1.5 mV respectively) were produced, stabilised and isolated into the solid-state with the 
help of montmorillonite (MMT) clay carrier particles. The nanoparticles of valsartan (50 nm), 
clozapine (27nm), curcumin (170 nm) and carbamazepine (30 nm) were produced and 
stabilized in suspension using a reverse antisolvent precipitation technique in the presence of 
‘as received’ MMT carrier particles (~30 m) and/or MMT carrier particles whose surface had 
been slightly modified with a cationic protein, protamine sulphate salt (PA). The resulting 
nanoparticle carrier composites were isolated directly from suspension into a solid-state form 
by simple filtration followed by air-drying. The API dissolution rates from these dried NP-
carrier composites were comparable with those of the respective polymer-stabilized API 
nanoparticles in suspension up to maximum valsartan, clozapine, curcumin and carbamazepine 
loadings of 33.3%, 23%, 21.8% and 33.3 % (w/w) respectively confirming that the high surface 
area of the nanoparticles is retained during the adsorption and drying processes.  
The dissolution profiles of these nanoparticles from their respective MMT/PA-MMT 
nanocomposites were shown to be influenced by parameters such as the zeta potential of the 
API nanoparticles, the degree of PA functionalization, and the API loading on the carrier 
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particle system. It has been found that for API nanoparticles with zeta potential more negative 
than ca. -25 mV, prior functionalisation of MMT’s surface with protamine (PA) was needed in 
order to preserve the fast API nanosuspension-like dissolution rates at higher API loadings. For 
these APIs, the optimal loading of PA on MMT was consistently around 4 mg/g, which likely 
helped to limit aggregation of the API nanoparticles thus facilitated the enhanced dissolution 
profiles of these API nanoparticles at higher loadings from the dried state. By contrast, API 
nanoparticles with zeta potentials less negative than ca. –25 mV did not require the MMT 
modification with PA in order to maintain enhanced dissolution profiles at high API loadings. 
Following the above studies, the technical feasibility of transforming this batch processing 
method of antisolvent precipitation, stabilisation and isolation for API nanoparticles into 
continuous processing was investigated. Specifically, a novel process was developed for the 
continuous carrier particle mediated stabilization and isolation of valsartan nanoparticles in a 
solid-state form using MMT as a carrier particle. Nanoparticles of valsartan (51±1 nm) were 
successfully prepared, stabilized and isolated into the dried form by this continuous route. The 
dissolution profile of the isolated valsartan nanocomposite solids was similar to that of 
valsartan nanocomposite solids produced via the corresponding batch mode process, 
confirming that the product quality is retained during the continuous processing of the 
nanoparticles. Furthermore, tablets produced via direct compression of the isolated valsartan 
nanocomposite solids displayed a dissolution profile comparable with that of the powdered 
valsartan nanocomposite material. The valsartan nanoparticles produced via this continuous 
process possessed shelf-life stability of  >10 months (based on accelerated stability storage 
conditions of 313 K and 75% relative humidity for 2.5 months), thus indicating the long-term 
stability potential of valsartan nanocomposites produced via this carrier particle mediated 






A schematic of the production and isolation of API nanoparticles in the presence of (i) soluble 
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One of the major challenges in the pharmaceutical industry is the poor solubility and slow 
dissolution rates of drugs. This problem has become more prevalent among new drug 
compounds in the last two decades. This is a consequence of the new paradigm in high 
throughput, proteomic, and combinatorial screening during drug discovery and selection 
phases, which is based on good affinity and specific binding with target receptors1–3. Most of 
the compounds that emerge from these studies are highly lipophilic (high log P values) because 
of the substantial emphasis on the interaction of the drug molecules with a defined molecular 
target during in vitro screening of the new drug candidates2,4. It has been estimated that almost 
90% of new drug candidates and 40% of the drugs currently in the market suffer from the 
problem of limited bioavailability due to their poor solubility and slow dissolution rates5–7. 
Poor aqueous solubility is one of the major challenges in the development of new oral drug 
dosage forms because dissolution is the first step in the absorption of the drugs8. Drug 
solubility, dissolution, and gastrointestinal permeability are the key determinants of oral 
bioavailability9,10. Drugs with low bioavailability are likely to either accumulate in tissue or be 
eliminated via a first-pass metabolism in the intestines or liver due to their high lipophilicity 
and low solubility11. For these drugs, consistent and enhanced bioavailability can be improved 
if the dissolution rate or saturation solubility can be sufficiently enhanced. Numerous 
approaches have been adopted to overcome the poor aqueous solubility of these drug 
candidates, which include salt formation, use of cosolvents12, solubilisation in surfactant 
solutions13, amorphous solid dispersions14, emulsions15–17, lipid-based formulations18, 
complexation with cyclodextrins19, micelles20 and pH adjusted solutions. However, most of 
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these techniques possess certain limitations such as suitable molecular size requirement for 
cyclodextrin complexation, physical and chemical stability issues of solid dispersions, 
requirements for a large amount of additives, etc2. In recent years, nanoparticle formulation 
techniques represent an interesting and potentially useful method for improving the 
bioavailability of highly water-insoluble drugs. Recent reports on the current market scenario 
estimate that the nanotechnology-enabled drug delivery will be $136 billion by 2021. Out of 
this a 60% (~$82 billion) share is expected to be occupied by nanocrystal formulations alone21. 
Nanoparticles, by virtue of their high surface area to volume ratio, result in enhancement of 
dissolution rates and a modest increase in saturation solubility of poorly water-soluble drugs 
and ultimately their bioavailability. Parameters that affect solubility and dissolution rates are 
described by the Ostwald–Freundlich equation and Noyes-Whitney equation respectively22–25. 
Consequently, nanoparticles have been extensively used for a variety of dosage forms to 
improve the bioavailability of poorly water-soluble drugs by utilizing the enhanced solubility 
and dissolution rate of nanoparticles26–28. Available commercial products relying on 










Table 1.1. Currently marketed pharmaceutical nanoparticles products and the process by 
which they are produced29–34. 









Cesamet® Nabilone Lilly Coprecipitation 
Naprelan® Naproxen sodium Wyeth Media milling 
Gris-PEG® Griseofulvin Novartis Company Coprecipitation 









Zanaflex tm® Tizaridine HCl Acorda Media milling 





Rapamune® Rapamycin/sirolimusna Wyeth Coprecipitation 
Emend® Aprepitant Merck Media milling 
Tricor® Fenofibrate Abbott Media milling 
Triglide® Fenofibrate Skye Pharma 
High pressure 
homogenization 
Megace®ES Megestrol acetate Par Pharma Media milling 
Invega Sustenna® Paliperidone palmitate Johnson & Johnson 
High pressure 
homogenization 
Avinza® Morphine sulfate31 King Pharma Media milling 
Ritalin LA® Methylphenidate HCl Novartis Media milling 
Hydrosol Cyclosporin Sandoz-Novartis 
Solvent-antisolvent 
precipitation 
Lucantin® β carotenoid BASF 
Precipitation 
(Nanomorphs) 









Drug nanoparticles can be obtained either by “top-down” (i.e. disintegration/comminution) or 
“bottom-up” (i.e. crystallization/precipitation) approaches. In “top-down” processes, larger 
particles are fragmented into smaller particles using various wet milling techniques28,35 (such 
as media milling, microfluidization, and high-pressure homogenization) or dry-impact 
milling36–38 (which includes hammer mills and ball mills, and more recently air-jet mills have 
been used to obtained micronized drug products). Although top-down technologies of various 
milling techniques are frequently used in the pharmaceutical industry, they suffer from 
problems including long milling times, phase transformations during milling, crystal defects 
due to damage and disordering of the crystal surface and degradation of heat-sensitive drugs 
due to heat generation during milling39–42. On the other hand in “bottom-up” processes, 
nanoparticles are obtained after recrystallization of the drug from a supersaturated solution, for 
example, antisolvent precipitation, supercritical fluid processes, spray drying, and emulsion-
solvent evaporation processes43. Nanoparticle production through liquid antisolvent 
precipitation (LAS) is one of the most attractive alternatives among all “bottom-up” 
techniques44. The product obtained from this process is a suspension of drug nanoparticles in a 
liquid (known as a nanosuspension) stabilized by a surfactant or polymers. It is very fast, 
simple, and cost-efficient because this technique provides a very convenient process at room 
temperature and atmospheric pressure with no requirement for expensive instrumentation44,45. 
It exhibits several other benefits such as the potential to produce high drug loadings, minimal 
use of organic solvents, efficient particle size distribution, and simple formulation composition.  
Despite several advantages of nanosuspensions, they present various drawbacks including 
nanotoxicity and stability issues28,46,47. Nanoparticles in suspension are thermodynamically 
unstable due to their high surface area. Thus, they tend to agglomerate or to undergo Ostwald 
ripening48 in suspension in order to minimize their excessive free energy47. 
Agglomeration/Ostwald ripening of nanoparticles in suspension during the production process 
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may directly impact in vitro dissolution and in vivo performance due to the formation of larger 
particles with reduced surface area47,49. Stabilizers such as polymers, surfactants and lipids are 
vital for preventing the aggregation of high energy nanosuspensions via electrostatic and/or 
steric effects. However, these stabilizers often can stabilize the nanoparticles in suspension for 
only short periods of time.  No single stabilizer is appropriate for all drugs and preparation 
processes50. Furthermore, the long term oral administration of large quantities of stabilizers has 
also limited the therapeutic application of nanosuspensions due to potential toxicity50,51. 
Isolation of drug nanoparticles from suspension into the dry state is crucial for prolonged 
stabilization and convenience during oral administration. An ideal isolation technique not only 
requires good physical stability of drug nanoparticles in the solid-state, but also must exhibit 
excellent in vitro dissolution and in vivo performance to retain the advantages gained from the 
high surface area of the nanoparticles33. Freeze drying, spray drying, and centrifugation are the 
most commonly used solidification techniques28,52. Although these conventional methods of 
drying nanoparticles have been actively adopted by the pharmaceutical industry, they have 
limitations. They are expensive and time-consuming and require high energies and some 
require manipulation at relatively high temperatures.  Aggregation of nanoparticles during 
drying can adversely affect the particle size distribution with consequential reduction in 
dissolution rates compared to fresh nanosuspensions28,53. Therefore, the development of a 
simple and efficient process to address the issue of stabilization and isolation of drug 
nanoparticles in the solid-state deserves significant attention. 
The objective of this project is to prepare, stabilize and isolate poorly water-soluble drug 
nanoparticles in the solid-state with the help of carrier particles in a batch as well as a 
continuous process in order to formulate them into fast-dissolving, solid-state nanoparticle 




Bioavailability is defined as “the rate and extent at which the active drug is absorbed from a 
dosage form and become available in the systemic circulation”54. It usually refers to the 
absorption of the drug from the gastrointestinal tract following the oral administration of 
dosage forms such as solution, suspension, tablet, capsule, powder, or elixir54. Bioavailability 
can also refer to other types of dosage forms such as intramuscular injections, transdermal 
patches, ointments, and other topical preparations, and implants which also require an 
absorption step prior to reaching the systemic circulation. The intravenously administered 
dosage form has 100% bioavailability since it is administered directly into the blood, therefore, 
the amount of drug reaching systemic circulation equals the total administered dose. When a 
medication is administered via other routes such as orally, its bioavailability decreases due to 
incomplete absorption, which varies from patient to patient. However, the oral route of 
administration of the drug is considered to be most convenient for ease of administration, 
patient compliance, ease of production, and scalibility5,55. Out of 48 drugs approved by FDA 
in 2019,  21 (~44 %) were for oral administration56. The most important factor characterizing 
the bioavailability of the orally administered drug is the dissolution rate of the drug because a 
drug must be in solution to be absorbed from the gastrointestinal tract. This project is focussed 
on improving the dissolution rate and ultimately bioavailability of poorly water-soluble drugs. 
Bioavailability mainly depends upon three factors, namely solubility, dissolution rate, and 
gastrointestinal permeability. Low solubility and/or low permeability often results in 
insufficient drug reaching the bloodstream or target tissues because good water solubility is 
necessary for a drug to dissolve in the body and good permeability is necessary for a drug to 
cross biological membranes and to enter the systemic circulation. Bioavailability of drug 
products can also be influenced by the physiology of the administered patients and other factors 
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such as the content of the gastrointestinal tract, rate of gastrointestinal tract transit, pre-systemic 
drug metabolism and/or degradation.  
Table 1.2. The steps involved to reach the target site upon oral administration of a 
pharmaceutical tablet in vivo and corresponding in vitro/in vivo experimental methodologies 
used to characterise these steps 54. 
Steps involved in-vivo  Experimental methodologies 
Dosage form disintegrates into smaller 
particles 
In vitro testing of disintegration 
Drug reaches the gastrointestinal membrane: 
 Drug is returned to the GI lumen by P-
glycoprotein efflux pump 
 Metabolism of the drug by intestinal 
enzymes 




           In vitro drug transportation studies 
 
           In vitro drug metabolism studies 
 
           In vivo hepatic profusion studies 
Dissolution of the drug in gastrointestinal 
fluids 
           In vitro dissolution testing 
Drug reaches systemic circulation Assay of the drug in blood plasma or serum 
Drug reaches its site of action and causes the 
pharmacological response 
Measurement of onset, intensity, and duration 










1.3 Biopharmaceutical classification 
The Biopharmaceutics Classification System (BCS) was devised by Amidon et al. in 1995 and 
since then has become a benchmark for guiding pharmaceutical scientists to develop strategies 
for improving the efficiency of drug development by proper selection of dosage form and 
bioequivalence tests9,55. In short, the BCS is used to correlate in vitro drug product dissolution 
and in vivo bioavailability. BCS takes into account of two major factors, namely solubility and 
gastrointestinal permeability, which govern the rate and extent of drug absorption55. Based on 
these two major factors drugs are classified into four categories as shown in Table 1.39,57. 
Table 1.3. The BCS classification of drugs and their % distribution of marketed drugs and 
drug candidates in 2017 (adapted from reference 57). 9,57 
Biopharmaceutical Classification System (BCS) 
Class I  
 High solubility 
 High permeability 
Marketed ~35%  
Candidates ~5% 
Class II 
 Low solubility 
 High permeability 
Marketed ~30% 
Candidates ~70% 
Class III  
 High solubility 
 Low permeability 
Marketed ~25%  
Candidates ~5% 
Class IV 
 Low solubility 




The classification boundaries used in the BCS are as follows: 
 a drug is said to be highly soluble when the highest dose strength is soluble in 250 mL 
of water over a pH range of 1 to 7.5, 
 a drug is said to be highly permeable when the extent of absorption in humans is 
determined to be 90% of an administered dose, based on mass balance or compared 
with an intravenous dose, and 
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 a drug substance  is considered to dissolve rapidly if 85% of the drug substance 
dissolves within 30 minutes in a volume of 900 mL buffer solution, using a United 
States Pharmacopeia (USP) apparatus I or II. 
BCS class II drugs are characterized by poor solubility, but have good ability to cross biological 
membranes. Thus, the bioavailability of these drugs can be increased by increasing their 
solubility and/or drug dissolution rate. This project will mainly focus on improving the 
dissolution rate, and thus the bioavailability, of poorly water-soluble BCS Class II drugs. 
1.4 Solubility and dissolution rate 
Solubility and dissolution rate are different concepts but are connected. The solubility of the 
drug is defined as “the maximum amount of solid dissolved in the solvent at a specified 
environmental condition”58. The maximum solubility at specified conditions occurs in the 
presence of excess solid. The solubility of the drug in aqueous solution is a fundamentally 
important property that plays a vital role in the absorption of the drug after oral administration 
as well as the ease of manipulation and testing of the drug during the drug design and 
development process59. The dissolution rate is the rate at which drug in a formulation passes 
into the solution58. The dissolution rate is also an important element in drug development since 
the intestinal transit time is finite; the rate of drug dissolution must significantly exceed the rate 
of intestinal transit for maximum absorption of a drug59. For example, a drug with high 
solubility may have poor absorption if the rate of dissolution is low because an acceptable 
solubility may never be reached during intestinal transit time. Similarly, a drug with low 
solubility and high dissolution rate may have poor absorption because the amount of drug 
available in the solution for absorption is too low to support the rates of flux across the intestine 
that are sufficient to absorb the entire drug dose in the time59. Solubility and dissolution are 
two distinct phenomena; solubility is a thermodynamic process, which tends to proceed to the 
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point of lowest potential energy (Gibbs free energy), while the dissolution rate is the kinetic 
process to attain the lowest Gibbs free energy58. 
The dissolution rate of a drug in a particular medium is defined as the amount of drug that goes 
into the solution per unit volume and time.  It can be expressed by the Noyes-Whitney 










= solute dissolution rate, m= mass of dissolved material, t= time, A= surface area of 
the solute particle, D= diffusion coefficient, d= thickness of concentration gradient, Cs= 
saturation solubility of the solute in the dissolution medium, and Cb= solute concentration in 
the bulk solution at time t. 
If we assume sink conditions, where the concentration of drug in bulk solution (𝑪𝒃) is very low 
relative to the concentration at the surface of the dissolving solid (saturation concentration, 𝑪𝒔), 







The schematic of drug dissolution from the solid state based on the above model is summarized 




                
 
 








Direction of diffusion 
Surface area (A) 
              (1.1) 
                (1.2) 
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Thus, to influence the dissolution rate of any drug one can tune the different parameters 
involved in the Noyes-Whitney equation as summarized below58. 
Diffusion coefficient (D): This decreases with increasing solvent viscosity, and as a result the 
dissolution rate, (dm/dt) decreases. Thus, D is inversely proportional to viscosity. 
Surface area of solute (A): This can be increased by reducing the particle size, and as a result 
the dissolution rate increases. 
Thickness of diffusion layer (d): Diffusion gradient can be decreased by increasing the agitation 
or stirring during the dissolution and as a result dissolution rate increases. 
Saturation solubility (Cs): This can be altered by changing the pH, which could either increase 
or decrease Cs depending upon the characteristic of solute and solvent, and as a result increase 
or decrease the dissolution rate. 
Concentration in bulk solution (Cb): This can be decreased by intake of fluid in the stomach or 
by removing the drug by partition coefficient, and as a result the dissolution rate increases. 
Thus, solubility and surface area are major determinants of drug dissolution. Since drug 
solubility depends upon crystal lattice and affinity of solute for the solvent, three major 
strategies can be defined to increase the solubility and dissolution rate as follows: 
 decreasing the intermolecular forces between the molecules in the solid state, 
  increasing the strength of solute-solvent interactions in solution, and 
 decreasing the particle size of the drug, which increases the surface area to volume 
ratio, thus increasing the solute-solvent interaction capability.  
The main focus of this thesis is to improve the dissolution rates of poorly water-soluble drugs 




Supersaturation is a direct measure of the chemical potential difference between a molecule in 
an equilibrium state (µeq) and a molecule in its supersaturated state (µss)
60–62. It is the driving 
force of crystallization in liquid solutions: 
                                              Δµ=µss - µeq  kTlnS 
where k is the Boltzmann constant, T is the absolute temperature, and the supersaturation S is 





where C is the actual concentration of drug in solution (mol/L) and 𝐂∗ is the equilibrium 
solubility (mol/L). 
In short, supersaturation is a non-equilibrium state, where a solution contains a larger amount 
of dissolved solute relative to equilibrium solubility of the compound63. 
When S> 1 the solution is supersaturated, and only then is nucleation and/or growth of crystals 
possible. When S=1 or S <1 the solution is said to be saturated and undersaturated respectively.  
The most common methods of generating supersaturation are by reducing solution temperature 
(cooling crystallization), evaporation of the solvent (evaporative crystallization), chemical 
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Crystallization is an important process occurring in nature and used in numerous industries 
including the chemical, food and pharmaceutical industries for separation and purification 
purposes. In the pharmaceutical industry, most of the drugs and their salts are purified and 
isolated by crystallization. Crystallization processes allow manufacturers to obtain desired and 
reproducible particle properties. The quality of crystalline products is based on four main 
properties: size, morphology, purity and crystal structure, because these individual 
characteristics can affect the physical and chemical properties of solids. Crystallization is a 
complex process which is completed in several stages64. The first stage is the formation of the 
supersaturated solution which is the driving force for the appearance of a new phase. The next 
stage is aggregation or clustering of molecules of the solute which eventually leads to the 
formation of nuclei of the critical size that can act as centres of crystallization. The final stage 
is the growth stage, which follows the nucleation, and which is governed by the diffusion of 
molecules to the surface of existing nuclei and their incorporation into the crystal structure. 
1.6.1 Nucleation 
Nucleation refers to the birth of small molecular clusters of a new phase within a supersaturated 
homogeneous existing phase64. In crystallization, nucleation plays a decisive role in 
determining the crystal structure and size distribution. Nucleation can be classified into three 




According to classical nucleation theory65, the formation of a new solid phase from 
supersaturated solutions in the absence of foreign particles and surrounding surfaces is termed 
as “homogeneous nucleation”. If existing foreign particles promote the nucleation it is termed 
as “heterogeneous nucleation”. Both are categorized as primary nucleation63. Most primary 
nucleation is in practice likely to be heterogeneous nucleation induced by other surfaces63. On 
the other hand, nucleation from the solution initiated by existing/added seed crystals combined 
with mechanical abrasion or thermodynamic effects is known as “secondary nucleation”63. 
1.6.1.1 Homogeneous nucleation 
Classical nucleation theory65 is the most widely used description of the nucleation process. It 
was originally derived for condensation of vapor into liquid, i.e. the formation of nuclei from 
supersaturated water vapour, and was conceptually transferred to the nucleation of crystals 
from solution. By the end of 19th century, Gibbs developed the thermodynamic description of 
this process, which described the free energy change required for cluster formation (𝚫𝐆) as the 
sum of two terms: the free energy due to the formation of a new volume (ΔGv) and the free 







(induced by foreign 
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ΔG= ΔGv + ΔGs 
In the case of crystallization from solution, ΔG describes the spontaneous tendency of a 
supersaturated solution to undergo deposition. The solid state is more stable than liquid, thus 
ΔGv becomes negative and lowers the overall Gibbs energy of the system by an amount 
proportional to the volume of deposition (proportional to r3). In contrast, the introduction of a 
solid/liquid interface is not energetically favorable, thus ΔGs becomes positive which increases 
the free energy by an amount proportional to the surface area of the cluster (proportional to r2).  
Thus, the overall growth of clusters depends on the competition between a decrease in ∆Gv, 
which favors growth, and an increase in ∆Gs, which favors dissolution (Figure 1.2)63,64. 
 










Figure 1.2. Free energy diagram of nucleation63,64. 
 
 














The total free energy (ΔG) increases initially due to positive surface energy ΔGs term, which 
dominates initially at smaller radii. The total free energy increases with an increase in cluster 
size and attains a maximum at the critical radius (rc) above which it decreases continuously. 
Growth then becomes energetically favorable, resulting in the formation of crystal nuclei, 
Figure 1.2. 
By expanding Eq. (1.5), considering homogeneous nucleation of a spherical cluster having 
radius r: 
ΔG = 4π r2γ − 
4
3
𝜋 r3 ΔGv  
 
where 𝚫𝐆 is the free energy change required for cluster formation, ΔGv is the free energy due 
to the formation of a new volume, γ is the interfacial energy at the solid-liquid interface. 
The critical radius (rc) of the cluster can be obtained by minimizing the Gibbs free energy: 
i.e.                                          
                                                        
          
𝑑(ΔG)
𝑑𝑟
= 0  
                                                      
From Eq. (1.6) 
 
4πr2 ΔGv − 8πrγ = 0 
From Eq. (1.7) 
                                                






                (1.6) 
               (1.7) 
                (1.8) 
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Substituting the value of ΔGv from Eq.  (1.8)  in Eq. (1.6) gives the critical free energy                   
( 𝜟𝑮𝑪𝒓𝒊𝒕): 






The growth of a cluster is governed by the Gibbs-Thomson equation66: 




,       𝑖. 𝑒.       𝑟𝑐 =
2γv
𝑘𝑇 𝑙𝑛𝑆
    
         
where S is supersaturation, ν is the molecular volume, T is the absolute temperature, and k is 
the Boltzmann constant. 
After substituting the value of 𝒓𝒄 into Eq. (1.9), we can express 𝜟𝑮𝒄𝒓𝒊𝒕:  





In the kinetic theory based on Gibbs formalism, the steady-state rate of nucleation (J) is defined 
as the number of nuclei formed per unit time per unit volume, which is expressed in the form 
of the Arrhenius rate equation as67:  
                                              





where A is pre-exponential factor required for nucleation. 
Therefore, the rate of nucleation in solution (J) after combining Eqs. (1.11) and (1.12) is given 
by: 
 




                  (1.9) 
              (1.10) 
              (1.11) 
              (1.12) 
               (1.13) 
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1.6.1.2 Heterogeneous Nucleation 
Practically, most primary nucleation is likely to be heterogeneously induced by other 
surfaces63. Heterogeneous nucleation occurs at the surface of foreign particles such as 
polymers, excipient, surfaces (of containers, bottles, vessels, etc.) or impurities like dust. The 
free energy needed for heterogeneous nucleation is the product of homogeneous nucleation and 
a function of the contact angle (θ): 
                                                             
                                                       ΔGheterogeneous = f (θ).ΔGhomogeneous        
 
where f (θ) is described by the expression67: 
                                                            f (θ)= 
2−3𝑐𝑜𝑠𝜃+𝑐𝑜𝑠3𝜃
4
            
where f (𝜃) is the heterogeneous nucleation factor based on the contact angle (𝜃) between the 
nucleating phase and the heterosurface. 
The rate of heterogeneous nucleation has the same form as that of homogeneous nucleation 
except that the surface energy of the solid-liquid interface (γ) is replaced by the surface energy 
of the precipitated solid-foreign interface63. A previous study in the literature suggests that the 
presence of a hetero surface promotes the nucleation by lowering the interfacial energy of 
aggregates68. However, a recent study published by our group suggested that the presence of 
microcrystalline cellulose (MCC) as a heterosurface did not influence the heterogeneous 
nucleation by lowering the interfacial energy required for nucleation but instead by increasing 
the pre-exponential factor; as such, the number of prenucleation clusters is increased because 
the presence of a heterosurface facilitates nucleus formation69. 
              (1.15) 
              (1.14) 
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1.6.1.3 Multi-step nucleation model 
Classical nucleation theory assumes that (i) the growth of a cluster takes place by attachment 
of single molecules at a time to an array, which is ordered from its inception, and (ii) the 
collision between two clusters or the break-up of the preexisting cluster into two or more 
clusters are ignored64. Instead, the cluster is assumed to be at rest without undergoing 
translational, vibrational and rotational motion. However, studies suggested that cluster-cluster 
interaction has a significant impact on the process of nucleation. In fact, experimental and 
theoretical studies have provided evidence that solute particles aggregate into small clusters 
first, then these small clusters come together to form a single large cluster, essentially a 
disordered mixture of solute and solvent, somewhat more concentrated in solute than the 
surrounding solution, which subsequently becomes ordered in a separate step64,70–72. Growth 





























1.6.2 Crystal growth 
Understanding the crystal growth gives the possibility to control particle size distribution, 
morphology, purity and crystal structure73. Nucleation is followed by crystal growth. Crystal 
growth is the final stage of the crystallization process. In this process, nuclei grow larger by 
the addition of solute molecules from the supersaturated solution67. The process involves the 
transport of molecules from the liquid phase through a diffusion layer surrounding the crystal 
(sometimes called volume diffusion step) followed by a surface integration step which consists 
of gradual desolvation of the molecule, surface diffusion over the crystal face, and its lattice 
integration into a favourable location67,74,75. Molecules tend to bond at the location where they 
have the maximum number of nearest neighbours as these are more energetically favourable 
sites67. The mechanism of incorporation of a molecule into a crystal face can be understood by 
schematic shown below Figure 1.4 where the adsorption of the molecule onto the surface 
(terrace) is followed by its diffusion along a surface to a step (ledge) or to a kink position for 
incorporation67. Kinks are the more energetically favourable site of incorporation, and hence 
offer the most stable configuration. Growth is then produced by attachment of growth units to 
kink sites Figure 1.467,74. 
 




The growth mechanism can be classified into three types based on the interface structure. If the 
surface is rough the growth will follow the rough interfacial mechanism, whereas if the surface 
is smooth the growth will take place either by the spiral growth mechanism (Burton- Cabrera-
Frank, BCF) or by the 2D nucleation and growth (birth and spread, B+S) mechanism67,74,76. 
High driving force conditions (i.e. high supersaturations) lead to the transformation of smooth 
to rough surfaces74. At low supersaturation, the interface is smooth and growth follows the 
BCF mechanism. After reaching a critical supersaturation, growth is dominated by the birth 
and spread mechanism. At high supersaturation, the transformation to a rough interface takes 
place and the rough interfacial growth mechanism dominates Figure 1.574. 
 






The rate of growth of a crystal has a complex dependence on external factors like temperature, 
supersaturation, size, habit, system turbulence, crystallization process, etc. as well as internal 
factors like molecular structure bonding and surface defects75. However, very commonly, a 
simple power law equation is used for crystal growth given by Nyvlt77 (Eq. 1.16), which only 
contains an explicit dependence on the supersaturation.  
 As such, the simple overall growth rate equation is: 
𝐺 = 𝑘′′𝑆𝑔 
 
where S is supersaturation, G is the growth rate, 𝒌′′ is the growth rate constant, and g is the 
kinetic order of growth (g  1-2). 
Crystal growth along with nucleation kinetics controls the final particle size distribution67. 
Control over nucleation and particle growth processes become crucial for the generation and 
stabilization of drug nanoparticles during “bottom up” nanoparticle production and thus the 













              (1.16) 
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1.7 Particle size reduction strategies to form drug micro/nanoparticles 
In the pharmaceutical industry, nanoparticles are defined as particles having sizes between a 
few nanometers and 1µm (1000 nm), and microparticles are defined as particles having a size 
range of 1-1000 µm78. As previously discussed, particle size reduction is the most common 
strategy to address the low solubility and dissolution rate of pharmaceutical compounds and is 
routinely used to improve the bioavailability of poorly water-soluble drugs79,80. Particle size 
reduction can influence both the dissolution rate (the Noyes Whitney equation, Eq. 1.1) and 
solubility (the Ostwald-Freundlich equation, Eq. 1.17 below). By decreasing the size of drug 
particles, dissolution rates increase because of the increase in surface area to volume ratio, thus 
increasing the surface area available for solvation (Eq. 1.1). Figure 1.6 shows how the surface 









Figure 1.6. Increase in the surface area obtained when the particle size is reduced from the 
micron-size range (microparticles) to the nanometer-size particles used in various 
nanoparticle formulations to enhance the performance of poorly water-soluble compounds49. 
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Decreasing particle size to the micron size has very little effect on equilibrium solubility 
because particle size changes in this range affect neither solid-state properties nor the efficiency 
of solvation. According to the Ostwald-Freundlich equation (Eq. 1.17), the particle size has an 
effect on solubility.  However, this only becomes significant with particle sizes below 1 micron 








     
 
where Cs is the saturation solubility, C∞  is the solubility of large size solid particles, γ is 
interfacial energy, vm is the molar volume, R is the gas constant; T is absolute temperature, r is 
particle radius, and ρ is the density of the solid. 
As discussed earlier, particle size can be reduced by either “top-down” approaches (i.e. 
disintegration/comminution) or “bottom-up” approaches (i.e. crystallization/precipitation). 









              (1.17) 
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Figure 1.7. Schematic of the top-down and bottom-up methods of producing nanoparticles. 
 
1.7.1 Top-down approaches 
In traditional “top-down” approaches, different dry-impact milling techniques have been used 
to obtain micronized drug products36–38. In these techniques, particle size is reduced via the 
fracture of large particles and the gradual attrition of the particle surface. However, these 
techniques are unable to produce drug particles within the nanometer range unless very long 
milling times are used and particles are also prone to phase transformation during milling39–42. 
In contrast, wet milling approaches such as pearl milling (alternatively known as nano milling 
or media milling) and high-pressure homogenization are capable of producing the drug 








1.7.1.1 Wet media milling 
This technique was first developed by Liversidge and co-workers80. It involves the continuous 
stirring and wet milling of a drug slurry in an aqueous or non-aqueous liquid medium with 
specialized milling pearls. From this technique, particle sizes less than 400 nm can be obtained 
via the combination of high-energy shear and impaction forces between the milling pearls and 
the solid drug particles35,81,82. Before milling initiation, the addition of drug-specific stabilizers 
to the aqueous slurry is essential to reduce the increase in free energy due to the formation of 
new particle surfaces, to inhibit crystal growth and to prevent agglomeration. However, recent 
studies suggest that the addition of stabilizers during milling facilitates the milling process83. 
The main drawbacks of this technique are traces of solvent and unmilled drug material 
remaining after size reduction, as well as the need for pre-downsizing of the starting material. 
Ye et al.84 reported the preparation by wet milling of niclosamide nanocrystals (235 nm) for 
parenteral administration, while Patel et al.85 utilized wet milling to produce nanosuspensions 
of efavirenz (320 nm) for improved oral bioavailability. Zhai and colleagues improved the 
media milling process of caffeine nanoparticles (250-660 nm) for dermal delivery by using 
Carbopol® 981 as a stabilizer in a medium of ethanol–propylene glycol (3:7), yielding 
nanoparticles that were stable up to 60 days at 4-25 o C86. Kakran et al.87 reported the preparation 
by wet milling of quercetin nanocrystals (276 nm) with superior saturation solubility as 




Figure 1.8. Schematic of the media milling process. The milling chamber is charged with 
milling media (e.g. polymeric milling beads), the particular drug, the stabilizer and a suitable 
solvent or mixture of solvents processed into a monocrystalline dispersion. Residence time 
needed to generate nanoparticles of size less than 200 nm is 30-60 min80,88 (adapted with 














1.7.1.2 High-pressure homogenization 
 High-pressure homogenization (HPH) is widely used to produce nanoparticles via the “top-
down approach” that was first developed by Muller et.al. in 199489. There are two different 
types of HPH techniques, namely microfluidization and piston-gap HPH; the latter is the more 
widely used technique to produce nanoparticles79. Insoluble Drug Delivery–Particles (IDD-
P™) technology (SkyePharma Canada Inc.) uses microfluidization techniques to achieve the 
production of submicron particles of poorly soluble drugs90. Microfluidization uses jet stream 
homogenizers such as the Microfluidizer® from Microfluidics Inc. to generate the 
nanoparticles via the collision of two fluid streams under pressure up to 1700 bar which leads 
to particle collision, shear forces and cavitation forces90,91. A relatively high number of cycles 
(50 to 100 passes) is necessary for a sufficient particle size reduction90. 
Different technologies which use piston-gap HPH include the DissoCubes® platform 
(SkyePharma AG, Muttenz Switzerland)92 and NanoPure® (PharmaSol, Berlin, 
Germany)59,90,93. The latter technology uses non-aqueous media to produce water-free 
nanoparticles. From HPH techniques, particle sizes of 50-400 nm can be obtained79. Several 
variables affect the size of the final product, such as residence time within the piston gap, and 
high velocity of material transfer during the HPH94,95. Therefore, to obtain the target particle 
size in the final product, the material must be repeatedly cycled through a homogenizer. 
Usually, 10-20 cycles are sufficient to achieve the minimum particle size, although a larger 
number of homogenizer cycles is required for drug particles that fragment poorly94,96,97. The 
use of concentrated drug suspensions provides a greater number of particle interactions and 
improves particle size reduction. However, this phenomenon is limited to 10% (w/w) loadings 
because it is very difficult to stabilize highly concentrated suspensions, and high energies are 
required to process highly viscous slurries26,98. HPH is well suited for the development of 
parenteral and oral formulations of poorly water-suitable drugs because there is no risk of 
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contamination from milling media. HPH is also able to eliminate potential microbial 
contaminants94,95,98,99. Several disadvantages of using HPH include long processing times when 
multiple homogenization cycles are required to reach the desired particle size. A larger 
minimum batch size is required as compared with pearl milling because of the higher void 
volume relative to most piston gap homogenizers.  The drug must be pre-milled before HPH 
to prevent blockage of apertures in the piston gap97,99. Table 1.4 summarizes the commercial 










Figure 1.9. Schematic diagram of high-pressure homogenization process. Drug microparticles 
are forced through a tiny gap in the micronizing zone which creates high turbulence and shear 















Wet media milling 
• Nanosuspensions can 
be prepared for various 
concentrations ranging 
from 1 mg/mL to 400 
mg/ml. 
• Wide size distribution 
in the nanoparticles35. 
• Energy efficient 
process 
• Time-consuming 
process and engenders a 
trace amount of 
impurities (e.g. solvents, 
unmilled drug materials, 
etc.) in products 
• It is very hard to scale 
up79. 











• Direct formation of 
nanosuspensions with 
narrow particle size 
distributions103 
• A large number of 
cycles required for the 
production of 
nanoparticles104. 
• A mixture of 
microparticles and 
nanoparticles is obtained 
for drug particles which 







• Can be used for poorly 
water-soluble drugs. 
• Easy to scale up with 
small batch to batch 
variations105 
• Production of 
nanosuspensions with 
high as well as low 
concentration  
• Nanosuspensions with 
narrow size   
distribution98. 
• Micrometer range size 
drug particles required 














1.7.2 Bottom-up approaches 
 In bottom-up methods, nanoparticles are be produced by crystallization/precipitation of the 
drug from supersaturated solutions106. These methods involve the generation of a 
supersaturated solution followed by the formation of crystal nuclei, which can subsequently 
grow. Achieving a high degree of supersaturation plays a critical role in nanoparticle formation 
as it leads to the formation of many small nuclei, the ongoing growth of which is restricted by 
rapid depletion of the supersaturated solute pool. A lower degree of supersaturation due to 
generation of a smaller number of nuclei and a slower depletion of the supersaturated pool 
allows crystal growth to be concentrated on a smaller number of nuclei and as a result, 
generates larger particles 59,106.  
The simplified rate of nucleation (N) and growth (G) which were defined by Nyvlt in 1968 
(Eq. 1.18 & 1.16) are expressed as a power function of supersaturation (S), given that n  5-15 
and g  1-267,77. There is a strong dependence of nucleation rate on supersaturation (S) as 
compared to the growth rate resulting in the formation of a large number of nuclei at high S. 
As a result of high nucleation, ongoing growth is restricted due to a reduction in the amount of 
solute available. Thus by increasing the nucleation rate to an extent where the growth becomes 
negligible, nanosized particles can be obtained. 
𝑁 = 𝑘′𝑆𝑛 
𝐺 = 𝑘′′𝑆𝑔 
where N is nucleation rate, 𝒌′is nucleation rate constant, n is kinetic order of nucleation, S is 
supersaturation, G is the growth rate, 𝒌′′ is growth rate constant, g is kinetic order of growth. 
Thus, very high supersaturation is necessary for the generation of nanosized particles. Different 
methods for the production of nanoparticles via the bottom-up approach are described below. 
              (1.18) 
              (1.16) 
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1.7.2.1 Spray drying 
Spray drying is one of the most common methods of solvent evaporation and is extensively 
studied. By this method, a high surface area for the solution is achieved which allows the rapid 
evaporation of the solvent and as a result, a high supersaturation is generated. In this technique, 
a drug substance is dissolved in a solvent, which is then pumped through a nozzle and atomized 
into a hot airflow. As a result, the solvent evaporates and a dry powder forms100,107. Rotary 
wheel (or disk) atomizers, pressure nozzles and two-fluid nozzles are the three major types of 
atomizers used in practice. During atomization, the atomizer turns the liquid feedstock into 
small liquid droplets. In general, the high atomizer pressure leads to smaller droplets and as a 
result, smaller particle sizes are obtained. There are three different air current systems with 
respect to spray drying100,108,109. If a heated drying medium is flowing in the same direction as 
the atomized feed, then it is termed as co-current flow. In this air current system, contact 
between the substance and hot air is minimal because of the rapid cooling of the air further 
below the chamber. It is mainly used for thermosensitive substances requiring minimum heat 
contact. Most food products are produced using a co-current spray drying system. If the 
direction of the heated drying medium and atomized feed is opposite, then the spray drying 
process is termed counter-current flow. It is mainly used for non-heat sensitive materials. This 
flow combines heat treatment and agglomeration effects which result in increased powder 
flowability and median particle size. The combination of co-current and counter-current flow 
in a spray dryer is termed mixed-flow spray drying.  
Until recently spray drying has been limited to the production of micron-sized particles. 
However, particle sizes in the range of 300-5000 nm can be produced by new generation spray-
dryers (for example, the Buchi B-90 from BUCHI Labortechnik AG, Flawil, Switzerland)59,110. 
These spray driers require only milligram quantities of drug and product can be obtained 
directly from solution in high yields (70-90%) and with minimal activity loss for a variety of 
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drug delivery applications110. The novelty of this spray dryer lies in the spray head (vibrating 














Figure 1.10. Schematic diagram of Nano Spray Dryer B-90110,111. 
 
Other common variants of solvent removal methods, such as evaporative precipitation into an 
aqueous solution (EPAS), have also been reported. During EPAS, a drug solution in an organic 
solvent is heated and sprayed in the form of droplets into a heated aqueous solution containing 
stabilizers112. The obtained suspension is then spray dried or freeze-dried to remove the solvent. 
Certain disadvantages of these processes include low production yield and degradation of heat-
sensitive drugs. It has recently been utilized in generating various amorphous nanoparticles of 





1.7.2.2 Supercritical fluids 
Using supercritical fluids (SCF) as an alternative to organic solvents in controlled 
crystallization is another well-studied bottom-up technology for the generation of 
nanoparticles. SCFs exist at a temperature and pressure above the critical point of a phase that 
combines the properties of gases and liquids as it can effuse through solids like a gas and 
dissolve materials like a liquid115,116. It is very easy to tune SCF solvent properties by very 
small changes in pressure and temperature close to the critical point117. Carbon dioxide (CO2) 
is the most commonly used supercritical fluid for pharmaceutical applications because it forms 
at a very practical critical temperature (304.2 K, 31.1°C) and pressure (7.38 MPa; 1070 psi)118. 
It is also nontoxic, nonflammable, inexpensive, and can be recycled. In the supercritical fluid 
antisolvent (SAS) technique, supercritical fluid is used as an antisolvent. There are different 
SAS methods where the SCF interacts with the drug solution differently119. For example, in the 
gaseous antisolvent (GAS) method, SCF is passed through the drug solution in the form of gas, 
whereas in the aerosol solvent extraction system (ASES) or the precipitation from compressed 
antisolvent (PCA) method, drug solution is sprayed in the form of fine mist into the chamber 
of compressed SCF116,120. Higher supersaturation generates in the PCA process compared with 
the GAS process because of the higher surface area of the aerosolized drug solution which 
results in a faster rate of mass transfer into the antisolvent121. Keeping this in view, York and 
co-workers developed the solution enhanced dispersion method by SCF (SEDS)122. In this 
method, conditions are adjusted such that CO2 remains in a supercritical state and a two-
channeled coaxial nozzle is used. This allows a high-velocity stream of supercritical CO2 to 
disperse and combine with a continuously flowing stream of drug solution; as a result, rapid 
nucleation and subsequent particle formation occur due to high rates of mass transfer between 
the SCF and the drug-containing solvent. Recent studies by Padrela et al.123 demonstrated the 
polymorphic control of carbamazepine using a supercritical-antisolvent crystallization using 
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the GAS method in combination with a certain additive type. In contrast, solvent crystallization 
through the evaporation method provided mixtures of different polymorphs when using the 
same set of additives. Thus, the SAS technique can also be used to control the polymorphic 
outcome of a drug. 
However, these processes have several disadvantages, such as the need for pressure pumps to 
generate high pressures, temperatures, and the need for specially designed nozzles which 
increase the cost of the technology115,116. Liquid antisolvent precipitation as discussed in the 
















1.7.2.3 Liquid antisolvent precipitation 
Nanoparticle production through liquid antisolvent precipitation (LAS) is one of the most 
attractive alternatives among all “bottom-up” techniques44. In this technique, a poorly water-
soluble drug is first dissolved in a solvent (in which it is highly soluble), which is then rapidly 
mixed with a solvent miscible antisolvent (a solvent in which the drug is poorly soluble, e.g. 
water). As a result, a high supersaturation is promptly generated due to the fast diffusion of 
solvent into the antisolvent, which thereby results in a fast nucleation rate (low critical free 
energy of nucleation) leading to the production of nanoparticles. The driving force for 
precipitation is the high supersaturations rapidly achieved124,125. The very fast rate of nucleation 
often results in amorphous nanoparticles, thus the term precipitation is frequently used instead 
of crystallization44. 
As mentioned above, to obtain nanoparticles with a narrow size distribution it is necessary to 
(a) create a high supersaturation, (b) ensure a uniform spatial concentration distribution of the 












LAS process parameters 
 Mixing 
During the LAS process, efficient mixing is needed to generate a uniform supersaturation. 
There are two important parameters associated with particle formation during precipitation, 
namely τmix (mixing time) and τprecipitation (precipitation time), where τprecipitation is composed of 
nucleation time and growth time. The ratio of τmix to τprecipitation is described by the 
dimensionless Damkohler number (Da) (Eq. 1.19)126–130. 




When Da >1, the mixing process is slower than the precipitation process and supersaturation 
is attained at a slower rate. The metastable zone is crossed very slowly which results in the 
dominance of particle growth leading to larger crystals. When Da <1, the process of mixing 
occurs faster than the precipitation process so the precipitation step controls the overall particle 
formation process. In this situation, the supersaturation is attained rapidly, thus the metastable 
zone is crossed very quickly, which results in the dominance of nucleation leading to a large 
number of nuclei and precipitation of ultrafine particles. Thus for the production of 
nanoparticles with a narrow size distribution, it is necessary to decrease τmix relative to 
τprecipitation.  
Antisolvent to solvent (AS/S) ratio 
This is an important parameter that affects the particle size during antisolvent precipitation. 
Supersaturation increases by increasing the AS/S ratio, thus increasing the nucleation rate. As 
a result, a large number of nuclei are formed leading to the formation of smaller particle sizes. 
In the subsequent growth phase, diffusion distance between the growing species increases due 
to a higher volume of antisolvent, with the result that diffusion becomes the limiting step for 
the growth of nuclei45,131,132.  




Temperature is an important governing factor which can change the final particle size 
distribution and the particles’ morphology. Usually, larger particle size is obtained when the 
precipitation occurs at higher temperatures due to an increase in solubility of the drug in the 
antisolvent-solvent mixture which results in a decrease in supersaturation and thus leads to 
larger particle size. At low temperatures, the solubility of the drug in the solvent-antisolvent 
decreases.  As a result, higher supersaturations and a decrease in growth kinetics at the crystal 
boundary layer interface are achieved, which result in smaller particle size132–135. Rate and 
extent of Ostwald ripening can also be decreased by lowering the temperature due to the 
decrease in solubility of drug in the antisolvent-solvent mixture136. 
 Drug concentration in solvent 
The size of precipitated particles is typically inversely proportional to the concentration of drug 
used, keeping all other parameters constant. The size of drug nanoparticles decreases with an 
increase in drug concentration because supersaturation increases which leads to a high 
nucleation rate. However increases in drug concentration beyond a certain limit can also 
encourage the resultant particles to agglomerate during the course of precipitation which leads 
to poor size distribution. This might be due to the formation of a large number of nuclei at the 
solvent/antisolvent interface which results in an increase in viscosity45,131,132,137. Due to the 
increase in viscosity of the drug solution, the diffusion of the drug between solvent and 
antisolvent decreases hence leads to non-uniform supersaturation and agglomeration. 
An overview of the advantages and disadvantages of the different bottom-up techniques is 






Table 1.5. Bottom-up methods with advantages and disadvantages11. 
Methods Advantages Disadvantages 
Liquid antisolvent process44 
• Cost and Energy 
efficient 
• One step process 
• Convenient process at 
room temperature and 
atmospheric pressure 
• Very fast process 
• Narrow particle size   
distributions 
• No requirement for 
expensive instrumentation 
• Agglomeration of 
nanoparticles after certain 
period of time 
• Rigorous screening of 
stabilizers required 
• Solvent and antisolvent 




• One step process. 
• Continuous and fast 
• Encapsulation can be 
possible by adding 
additives in the feed 
solution 
• Energy and thermally 
inefficient 
• Efficiency loss when  
milder experimental  
conditions are needed 
Supercritical antisolvent 
precipitation (SAS)138. 
• Mild conditions needed 
• Drug does not need to be 
miscible with a 
supercritical fluid, thus 
SAS can be used to a 
broad range of materials. 
• Recrystallization can be 
controlled, thus easy to 
tune the particle size and 
morphology 
• Immediate work up 
required, otherwise particle 
can change morphology 
and size 
• Solvent needs to be 




Gas antisolvent (GAS)139 
• Mild conditions needed 
which can allow the 
handling of proteins. 
• Potential to control  the 
polymorphism of the 
drug123 
• Efficient solvent 
removal after precipitation  
• Drug does not need to be 
miscible with supercritical 
fluids. 
• Can be used for a broad 
range of materials. 
 
 
• Batch process, difficult to 
scale up. 
• Difficult to separate gas 


















Stabilization of nanoparticles is critical to ensure their usability in various dosage forms 
including oral, parenteral, ocular, pulmonary, dermal and other specialized delivery 
systems26,27,140. Stability issues regarding nanosuspensions have been widely investigated and 
can be categorized as physical and chemical stability issues141. The most common physical 
stability issues include agglomeration, secondary crystallization, sedimentation/creaming, and 
Ostwald ripening. The large surface area to volume ratio of nanoparticles creates excessive 
surface energy, which is thermodynamically unfavorable.  As a result, the particles tend to 
agglomerate in order to minimize their excessive surface energy. Agglomeration affects the 
overall stability of nanoparticle formulation and can affect the various dosage forms 
differently142. During sedimentation, drug particles can either settle down or form a creamed 
particle layer in the formulation medium. The sedimentation rate is described by Stokes’ law 
which depends upon particle size, medium viscosity and density difference between the 
medium and the dispersed phase142. In secondary crystallization, incorporation of additional 
available molecular segments onto established crystal in the mother liquor causes them to grow 
resulting in bigger particle size. In Ostwald ripening, larger particles grow at the expense of 
smaller particles due to higher saturation solubility of smaller particles than the larger ones 
creating a drug concentration gradient between the small and large particles142. As a result, 
molecules diffuse from the higher concentration surrounding small particles to lower drug 
concentration around larger particles causing growth of larger particles. This promotes the 
dissolution of small drug particles into the bulk medium, which continues until all the small 
particles are dissolved. 
The stability of nanosuspensions also depends upon different colloidal interactions such as 
attractive, repulsive and steric forces47. Therefore, nanoparticle stabilization is achieved by 
minimizing these colloidal interactions. There are two approaches to stabilize these 
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nanoparticles, namely thermodynamic and kinetic. The kinetic approach uses an energy input 
to compensate for the excess surface energy generated due to the formation of nanoparticles. 
Kinetic energy in the form of ultrasonic waves, or high jet velocities generated by rapid mixing 
devices, are used to provide high-density energy dissipation which increases the kinetic energy 
of nanoparticles thereby inhibiting agglomeration to some degree. As a result, stabilization of 
nanoparticles is achieved. On the other hand, the thermodynamic approach uses stabilizers to 
mask the surface functional groups available on the particle surface and thus reduce particle-
particle interactions. Various ionic and non-ionic stabilizers are used to stabilize nanoparticles 
in suspension by electrostatic repulsion and steric stabilization mechanisms respectively during 
liquid antisolvent precipitation.26,142 These are described immediately below. 
Steric stabilization 
In steric stabilization, non-ionic polymers (polyvinyl alcohol (PVA), polyvinylpyrrolidone 
(PVP), polyethylene glycol (PEG), pluronic F-127 and F128, hydroxyl-propyl methylcellulose 
(HPMC), etc.) are used to provide steric stabilization of nanoparticles. During steric 
stabilization, polymer molecules adsorb onto the drug particle through non-specific 
interactions between the hydrophobic groups of the drug and the polymers44.  
The literature describes several mechanisms for the steric stabilization of nanoparticles such as 
hydrogen bonding, hydrophobic interactions, solvent-polymer interaction, drug-polymer 
interaction, and drug-polymer-solvent interaction44. In drug-polymer interaction, the portion of 
polymer adsorbed on the drug particle is called ‘the train’, while the portion extending away 
from the surface of the drug particle is called ‘the tail’. When two colloid particles come 
together the stabilizing tails may interpenetrate each other, depending upon the solvent used. 
When a solvent with effective dispersive properties is used as a bulk medium to stabilize a tail, 
interpenetration becomes thermodynamically unfavorable and it prevents particles from 
agglomerating in the medium141,142 Figure 1.11. Thus the interaction between the solvent and 
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the stabilizer’s tail can play an important factor in stabilizing drug nanoparticles through steric 
stabilization. Drug molecules and stabilizers can interact through hydrogen bonding which 
results in a reduction of solid-liquid interfacial energy81,127. Stabilizers like PVP and HPMC 
are reported to stabilize drug nanoparticles due to hydrogen bonding interactions between their 
hydroxyl groups on the polymer and complementary functional groups present in the 
drug81,127,143,144. Stabilization by hydrophobic interaction is achieved by the formation of a 
mechanical barrier against growth by occupying the adsorption sites, thus inhibiting the 
incorporation of drug molecules from solution into the crystal lattices143,145. Drug-polymer-
solvent interactions also play an important role in the stabilization of nanoparticles, which 
depend upon the polarity of the solvent used. The polarity of solvent plays an important role in 
the interaction of solvent with drug and polymer, which affects the relative diffusion rates of 
polymer and drug molecules towards the solid-liquid interface. There have been reports which 
showed that the slower diffusion of drug molecules and relatively quick adsorption of stabilizer 
molecules onto the drug nanoparticle surface leads to inhibition of growth, as a result, smaller 

















Figure 1.11. Illustration of the steric stabilizing/destabilizing mechanism of nanoparticles in 
suspension. If the solvent (red spheres) is an effective dispersion medium, the adsorbed layers 
of polymer on the dispersed particle surfaces cannot interpenetrate during collisions between 
particles, resulting in a stable suspension (left). On the other hand, if the solvent is a poor 
dispersing medium, the adsorbed layers of polymer on the dispersed particle surfaces 
interpenetrate resulting in particle aggregation (right)47. 
Electrostatic stabilization 
In electrostatic stabilization, ionic surfactants (sodium dodecyl sulphate (SDS) or sodium lauryl 
sulphate (SLS), docusate sodium (DOSS), sodium deoxycholate (NaDC), lecithin, etc.) and 
ionic polymers (chitosan, sodium alginate, etc.) are generally used to stabilize the drug 
nanoparticles via electrostatic repulsion44. Electrostatic stabilization of the nanoparticles is 
attributed to the formation of repulsive Coulomb forces between the charged colloidal 
particles44,146. Stabilization from electrostatic repulsion can be described by the Derjaguin-
















Figure 1.12. Illustration of classical DLVO theory showing potential energy versus distance 
between particles. Attractive forces (VA) are dominant at very small at large distances, while 
repulsive forces are dominant at intermediate distances thus creating a net repulsion between 
dispersed particles, preventing particle agglomeration47. 
This theory is only valid for nanoparticles in aqueous suspension149. Accordingly, the forces 
acting on colloidal particles are repulsive electrostatic and attractive Van der Waals forces. 
When nanoparticles formed in aqueous solution contain ions, counterions are attracted and co-
ions are repelled. As a result, an electrical double layer exists around each particle, which 
consists of two parts, an inner region (Stern layer) where ions are strongly bound and an outer 
(diffuse) region where they are less firmly bound; within these regions the particle acts as a 
single entity. When the particle moves (e.g. due to diffusion), ions within the boundary move 
with it, but any ions beyond the boundary do not travel with the particle. This boundary is 
called the surface hydrodynamic shear or slipping plane. The potential at this boundary is called 
the zeta potential (Figure 1.13). The zeta potential of drug nanoparticles provides a measure 
of its stabilization in suspension. The dividing line between a stable and unstable suspension is 
generally taken at either +30 mV or -30 mV. In other words, particles with zeta potentials more 
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positive than +30 mV or more negative than -30 mV generally form stable suspensions, through 
repulsion. The adsorption of surfactant molecules to the particle surface decreases the particle’s 
hydrophobicity, thereby reduces the hydrophobic forces of attraction (Van der Waal 
interactions), and as a result, reduces particle aggregation78. The concentration of surfactants 
also plays an important role in the electrostatic stabilization of drug nanoparticles. Only 
concentrations of surfactants below the CMC (critical micellar concentration) will actively take 
part in the stabilization of drug nanoparticles by adsorbing strongly onto particle surfaces. 
However, concentrations above the CMC cause the formation of micelles instead, and, as a 
result, leave the particle unprotected127,150. 
 
 
Figure 1.13. Illustration of DLVO theory of electrostatic stabilization of drug nanoparticles 
and formation of the electric double layer around a particle in suspension along with their 
potential at each boundary. The electric double layer consists of an inner region (Stern layer) 
where ions are strongly bound and an outer (diffuse) region where they are less firmly bound; 
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1.8 Isolation of nanoparticles to the solid state 
Isolation of nanoparticles from suspension to the dried state is crucial for their long-term 
stabilization and for the formulation of solid state oral drug delivery systems such as tablets. 
Freeze drying, spray drying and centrifugation are commonly used methods to convert 
nanosuspensions to the dried solid state. As previously outlined, although these methods of 
drying nanoparticles have been actively adopted by the pharmaceutical industry, they have 
certain limitations, such as high energy requirements, long processing times, and aggregation 
of nanoparticles during drying which can adversely affect the particle size distribution and 
result in a reduction in in vitro dissolution rates and in vivo performance due to the formation 
of larger particles with reduced surface areas28,53. Additional excipients 
(lyoprotectants/cryoprotectants) are often required during the drying (spray drying/freeze 
drying) process in order to minimize the aggregation after drying. Lactose, sucrose, etc. are 
typical sugar-based matrix formers frequently used as drying protectants151,152. However, 
drying protectants and their concentrations are selected on a trial and error basis, which requires 
rigorous screening153. Other drawbacks associated with protectants include the hygroscopic 
and amorphous nature of spray-dried sugar which leads to poor flowability, redispersion and 
dissolution behaviour of dried nanoparticles154. Utilization of alternative insoluble matrix 
formers such as microcrystalline cellulose (MCC), SiO2, CaHPO4, etc. during spray drying of 
drug nanosuspension have been also reported in the literature in order to preserve the high 
dissolution rate of drug nanoparticles after drying151. Recently, Tan et al. reported MMT clay 
as an alternative matrix former in the spray drying of a fenofibrate nanosuspension to preserve 
high dissolution rates after drying155. Some alternative isolation techniques have been 
demonstrated for isolating the nanoparticles from suspension into solid state,  including 
nanoparticle coating onto water-soluble carriers in a fluidized bed156, spray granulation with 
carrier particles157, nanoparticle incorporation into polymer films158, embedment of 
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nanoparticles in an elastic hydrogel matrix159, biocompatible alginate microparticles for 
encapsulation of hydrophobic and hydrophilic drugs160 and reversible salt- flocculation and 
filtration161. However, most of these techniques possess certain limitations such as strong 
interaction between the drug and polymer films during nanoparticle incorporation into polymer 
films which can adversely affect the release behaviour of drug nanoparticles158, formation of 
agglomerates during spray granulation process thereby comprising their dissolution rate157, use 
of drying protectants to minimize the aggregation, but concentration up to 1.5 times with 
respect to drug content were required in case of conversion of nanosuspension into solid state 
by fluidized bed process156, etc. 
In 2014, Khan et al. first reported a carrier-mediated isolation of ibuprofen and glibenclamide 
nanocrystals using inert dibasic calcium phosphate as carrier particles162. Carrier particle-
mediated isolation of these nanoparticles from suspension into a solid form was achieved by 
adding the carrier particles shortly after nanosuspension production (prepared either by milling 
or antisolvent precipitation), followed by stirring. The resultant nanoparticle (NP) carrier 
composites were filtered followed by air drying. The drug dissolution rates from these dried 
NP-carrier composites were comparable with those of the respective stabilized drug 
nanoparticles in suspension. However, the maximum drug loading on these carrier particles 
was very low, approximately 0.35% (w/w), which restricts its use to highly potent low-dose 
products 162. In addition, drug-specific stabilizers were required for these ibuprofen and 
glibenclamide NP carrier composites162,163. Our group has previously reported a one-step 
approach for preparing, stabilizing and isolating the nanoparticles of two poorly water-soluble 
BCS class II drugs, fenofibrate and mefenamic acid (200-300nm), using montmorillonite 
(MMT) clay particles as carrier particles164 without any use of drug-specific stabilizers. The 
dissolution rates of these drugs from their dried NP-carrier composites were comparable with 
those of the respective stabilized drug nanoparticles in suspension with maximum drug 
49 
 
loadings of 9.1% and 4.8% (w/w) respectively164. It was necessary to functionalize the surface 
of the MMT with protamine sulfate salt (PA), a polycationic peptide165 to prevent nanoparticle 
agglomeration at these loadings. The dissolution rates of fenofibrate and mefenamic acid from 
their respective MMT or PA-MMT nanocomposite solids were shown to be influenced by 
parameters such as nanoparticle size, the extent of PA functionalization and the drug loading 
























1.9 Conclusion and project goal 
Although  “top-down” technologies of various milling techniques are frequently used in the 
pharmaceutical industry, they have their own limitations, such as difficulty in controlling 
particle size and morphology, chemical degradation, contamination and solid-state changes of 
the micronized product43,47,166,167. They also require long processing times to reduce the particle 
size to less than 100 nm43. 
On the other hand, the “bottom-up” approach, which includes liquid antisolvent precipitation, 
is a fast, simple, and cost-efficient technique of generating nanoparticles126,168. However, 
nanoparticles in suspension are unstable, tending to agglomerate or undergo Ostwald ripening48 
in order to minimize their excessive surface energy47. The use of various soluble stabilizers 
such as surfactants, polymers and lipids is critical to the generation of physically stable 
nanoparticles by reducing the surface energy of nanoparticles via steric and/or ionic 
stabilization47,49. Although surfactants, polymers and lipids can act as temporary stabilizers to 
retard the growth process of nanoparticles, prolonged stabilization can only be achieved by 
isolating them into a solid-state form169. Once isolated, however, it is important that the 
nanoparticles remain in the non-aggregated form to retain their advantages for bioavailability 
enhancement169,170. There are many reports available in the literature on the use of liquid 
antisolvent precipitation for the generation of nanoparticles44. However, their isolation from 
suspension into the dried state is a research area that has been relatively neglected. 
The development of a simple, inexpensive and effective process of stabilization and isolation 
of drug nanoparticles in the solid-state that retains the high surface area of the nanoparticles is 
a research area that deserves significant attention. An ideal isolation technique not only must 
ensure good physical stability of the drug nanoparticles in the solid state, but also must allow 
the isolated nanoparticles to exploit the advantages of their high surface area to exhibit 
excellent in vitro dissolution rates and in vivo performance33. 
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The carrier particle technology using montmorillonite (MMT) clay (discussed in section 1.8) 
was observed to be a very simple and effective nanoparticle stabilization and isolation 
technique which successfully stabilized and isolated the nanoparticles of fenofibrate and 
mefenamic acid in the solid state with the retained high surface area of nanoparticles at loadings 
of less than 10% w/w using protamine (PA) as a surface functionalising group164. However, 
the application of this PA-MMT composite as a generic carrier particle system for nanoparticles 
of other drugs of different chemistry, particle size, and zeta potential had not been explored 
when this project commenced164. 
Therefore, the goal of this project was to prepare, stabilize and isolate nanoparticles (NPs) of a 
range of poorly water-soluble drugs in a batch as well as a continuous process in order to 
enhance their dissolution rate and ultimately bioavailability. The approach taken to achieve this 
goal was to generate nanoparticles of these drugs in suspension via antisolvent precipitation, 
to then stabilize them on a carrier-particle system without use of any drug-specific stabilizer, 
and thereafter to isolate the resultant nanoparticle composites from suspension into a solid form 
by simple filtration followed by air drying. In summary, the project aims were: 
(i) to stabilize and isolate NPs directly from suspension, for a range of poorly water- 
soluble  drugs, without the use of any drug-specific soluble stabilizers, 
(ii) to investigate the effect of protamine in modifying MMT and how this modification 
influences the ability of the MMT to stabilize a range of drug nanoparticles,  
(iii) to demonstrate the scalability of the process in terms of the technical feasibility of 
transforming this batch processing of antisolvent precipitation, stabilisation, and 




(iv) to simplify the drug nanoparticle formulation process by reducing the need for 
additional excipients when formulating them into final drug products (e.g. tablets) 
























Materials and Methods 
 
In this chapter, a brief description of materials, experimental setups, experimental procedures 
and the main characterization techniques are given.  
2.1 Materials 
Active Pharmaceutical Ingredients (APIs) 
The APIs studied in this thesis are Valsartan (Val), Carbamazepine (CBMZ), Clozapine 
(CLO) and Curcumin (CUR).  
2.1.1 Valsartan 
Valsartan (Val) ((S)-3-methyl-2-(N-{[2′-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl} 
pentanamido) butanoic acid, MW 435.5 g mol-1)  was generously supplied by Novartis, Ireland. 
Valsartan Form E (CCDC KIPLIG) was prepared from the as-received form according to the 
procedure outlined in the experimental section (section 2.2.1). Valsartan has been classified as 
poorly water-soluble drug. It is sold under the trade name Diovan. It is a non-peptide tetrazole 
derivative which contains an acidic tetrazole group (pKa = 4.73) as well as a carboxylic group 
(pKa = 3.9)
171. Val belongs to the family of angiotensin II receptor antagonists which control 
blood pressure and is used in the treatment of hypertension171,172. There is one known 
polymorph (Form E)173, an ethanol solvate (Form F)173, an octahydrate174 and three salts 
namely; calcium valsartan tetrahydrate175, magnesium valsartan tetrahydrate175, and 
dipotassium valsartan tetrahydrate175 reported in the Cambridge Structure Database (CSD). 












Figure 2.1. Chemical structure of valsartan. 
2.1.2 Carbamazepine 
Carbamazepine Form III (CBMZ, >98% pure, MW 236.3 g mol-1, CCDC CBMZPN01), 5H-
dibenzo[b,f]azepine-5-carboxamide, was generously supplied by Novartis, Ireland and used as 
received. It is sold under the product brand name, Tegretol. It is an anticonvulsant (also known 
as an antiepileptics) and analgesic drug used for treating epilepsy176. It is also effective in the 
treatment of a certain type of nerve pain called trigeminal neuralgia. Apart from the above uses, 
it was also the first anticonvulsant drug used in the treatment of bipolar disorder177. It is 
classified as a BCS class II drug as it has high intestinal permeability, with low water solubility. 
CBMZ is known to crystallize into five anhydrous polymorphic forms (Form I-V), one 
dihydrate, and several other solvates178,179. Form V is less common than the other polymorphs. 
The thermodynamic stabilities of the anhydrous form (Form I-IV) at room temperature have 
been reported to be in order:  III> I> IV> II180. All CBMZ anhydrous forms tend to convert 
into the dihydrate form via solution mediated transformation as the dihydrate form is the most 
stable form in aqueous environments181. 
 
                               
 









2.1.3 Clozapine base  
Clozapine base (CLO, >98% pure, MW 326.8 g mol-1, CCDC NDNHCL01), 3-chloro-6-(4-
methylpiperazin-1-yl)-11H-benzo[b][1,4]benzodiazepine was generously supplied by 
Novartis, Ireland and used as received. It is sold under the brand name Clozaril among others. 
It is classified as an atypical antipsychotic agent. It is mainly used to treat schizophrenia182–184. 
It also helps to decrease the rate of suicidal behaviour in those diagnosed with schizophrenia 
and schizoaffective disorders. Clozapine is associated with several side effects, some of which 
are serious and may result in death. Some of the common side effects include drowsiness, low 
blood pressure, dizziness, high risk of low white blood cells, etc. CLO is known to crystallize 
into one polymorph185 (CCDC NDNHCL01), one monohydrate, a methanol solvate186, an 
ethanol solvate187, and four salts namely clozapine dibromide185, 3,5-dinitrobenzoate188, 
hydrogen maleate188, and 2-hydroxybenzoate188. Clozapine has been classified as a BCS class 
II drug due to its high permeability and poor water solubility182. 
 














Curcumin Form I (CUR) (~78% pure, MW 368.4 g, CCDC BINMEQ), 1, 7-bis(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione, was purchased from Sigma Aldrich (Ireland) and 
was used after recrystallization from isopropyl alcohol (IPA) to get >99% pure curcumin. CUR, 
a pharmaceutically viable ingredient, is a major active component of the Indian spice turmeric 
(Curcuma longa). It has a wide range of pharmacological properties such as antimicrobial, anti-
inflammatory, anti-angiogenic, antioxidant, anticancer, anti-HIV agent etc.189–191. CUR is 
known to crystallize into three different forms (Form I-III)191,192. CUR has been classified into 
poorly water-soluble drug. 
 
 















Four different excipients were used in this thesis: Pluronic F-127, hydroxypropyl 
methylcellulose (HPMC), protamine sulphate salt (PA), and montmorillonite clay (MMT). The 
first three were dissolved in water and used in aqueous form while MMT was used as a powder 
form. All the excipients is classified by the US Food and Drug Administration (FDA) as 
“generally recognised as safe” (GRAS)193. 
2.1.5 Pluronic F-127 
Pluronic F-127, also known as Poloxamer 407, is a non-ionic triblock co-polymer of poly 
(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) (PEG-PPG-PEG). It is 
amphiphilic in nature due to the presence of the hydrophobic central segment of PPG and the 
two hydrophilic side segments of PEG7. Poloxamers are widely used in the field of pharmacy 
and biomedicine as soluble stabilizers, thermosensitive hydrogels, nanoparticle and micelle 
carriers, for particle surface coatings etc7,194. Today they are especially utilized to stabilize 
poorly water-soluble drug nanoparticles in suspension due to the presence of their hydrophobic 
core194. In this thesis, Pluronic F-127 is used as a soluble stabilizer of valsartan and clozapine 
nanoparticles in suspension. Pluronic F-127 (MW~ 12.5 kDA) was purchased from Sigma 
Aldrich (Ireland) and used as received without further purification. 
  
 











2.1.6 Hydroxypropyl methylcellulose (HPMC) 
Hydroxypropyl methylcellulose, commonly known as hypromellose, is a mixed alkyl 
hydroxyalkyl cellulose ether containing methoxy and hydroxypropyl groups195. The hydration 
of HPMC depends upon the degree of substitution of methoxy and hydroxypropyl groups195. 
HPMC is commonly used in hydrophilic matrix drug delivery systems as well as an excipient 
in tablet or capsule manufacturing195,196. It is also used to stabilize nanoparticles in suspension 
via hydrogen bonding interaction between their hydroxyl groups and complementary 
functional groups present in the drug molecule. In this thesis, HPMC is used as a soluble 
stabilizer to stabilize carbamazepine nanoparticles in suspension. HPMC (MW~ 26 kDA) was 































2.1.7 Polyvinylpyrrolidone (PVP) 
Polyvinylpyrrolidone, commonly known as povidone, is a linear water-soluble polymer made 
from 1-vinyl-2-pyrrolidine monomers. It is a bulky non-ionic polymer widely used in 
nanoparticle synthesis197. It contains a strong hydrophilic component (the pyrrolidone moiety) 
and a considerable hydrophobic group (the alkyl chain)197. It is used as a binder in 
pharmaceutical tablets, emulsion stabilizers, film former, etc. It is very effective in stabilizing 
nanoparticles in suspension via repulsive forces which arises from the hydrophobic carbon 
chains that extend into the solvent and prevent particles from agglomerating in the medium 
(steric hindrance effect)197. In this thesis, it is used as a soluble stabilizer to stabilize curcumin 
nanoparticles in suspension. PVP K 30 (MW~ 40 kDa) was purchased from Sigma Aldrich 
(Ireland) and used as received without further purification. 
 
                  












2.1.8 Carboxymethyl cellulose (CMC) 
CMC is a chemically modified derivative of cellulose with carboxymethyl groups (-CH2-
COOH) bound to some of the hydroxyl groups of the glucopyranose monomers, formed by the 
reaction of monochloroacetic acid with alkali cellulose198. It has a β (1-4) glucopyranose 
polymer chain of glucose with a degree of substitution in the range of 0.6-0.95 derivatives per 
monomer unit. It is a white, fibrous, free-flowing powder generally used as an FDA approved 
disintegrant in the manufacturing of pharmaceutical tablets. It is used in various other products 
as a viscosity modifier or thickener in various food products, various paper products, water-
based paints, eye drops, etc. In this thesis, it is used as a disintegrant in the tablet formulation 
of Val-MMT nanocomposite (NC) solids. CMC fibrous form (amorphous, MW 100-200 kDA) 
was purchased from Sigma Aldrich (Ireland) and used as received without further purification.      
  
                           















R= H or CH2CO2H 
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2.1.9 Protamine sulfate salt (PA) 
Protamine sulfate salt is a positively charged small polycationic peptide derived from salmon 
that binds and precipitates DNA165. It has antibacterial properties and widely used in 
medication to neutralize the anticoagulant activity of heparin199. In this thesis, PA is used as a 
functionalizing agent to functionalize the surface of negatively charged montmorillonite clay 
(MMT). Protamine sulfate salt from salmon (PA, amorphous, MW~ 5.1 kDa) was purchased 
from Sigma Aldrich (Ireland) and used as received without further purification. 
 
 




















2.1.10 Montmorillonite (MMT) 
MMT (amcsd 0002868) is an example of smectite clay. MMT has a layered lattice structure 
consisting of two fused siloxane tetrahedral sheets sandwiching an edge shared octahedral sheet 
composed of aluminum or magnesium hydroxide.200,201 (Figure 2.10). The atoms within the 
single layer of MMT are strongly bonded to each other through electrostatic forces and the 
adjacent layers are held by weak interactions such as dipole or van der Waal forces 200. MMT 
has an overall negative surface charge due to imperfections in the crystal lattice and the 
isomorphous substitution in which Si4+ is substituted by Al3+ in the tetrahedral sheet and Al3+ 
is replaced by Mg2+ in the octahedral layer201,202. Due to its large specific surface area, it 
exhibits several properties such as good adsorbance, cation exchange capacity, standout 
adhesive ability, and drug-carrying capability201. It has a 2:1 layered structure203. The interlayer 
spacing of MMT (gallery) is 0.9-1.2 nm200. Water molecules can be intercalated between the 
clay layers that cause swelling due to the formation of interlayer ionic solutions203–206. Another 
characteristic associated with MMT is its basal space also known as d spacing (d001) which 
comprises the dimension of a layer plus a gallery (Figure 2.10). The basal spacing of MMT 
can be measured or characterized by X-ray diffraction. The surface of MMT contains dangling 
hydroxyl end groups and siloxane surface groups207–209. In this thesis, MMT is used as a carrier 
to stabilize and isolate drug nanoparticles. Montmorillonite K10 (MMT) was purchased from 






Figure 2.10. Schematic of MMT210. 
 
2.1.11 Solvents 
Methanol (MeOH, > 99 % purity) and acetone ((CH3)2CO, > 99 % purity) were purchased from 
Sigma Aldrich (Ireland) and used as received without further purification. Methanol was used 
as the solvent for valsartan, clozapine, and carbamazepine while acetone was used as the 
solvent for curcumin. Both are selected as solvents in this study as these are completely 
miscible with water (used as the antisolvent in this study) and the APIs are highly soluble in 
the selected solvents. 
Si or Al 
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2.2 Experimental Methods 
2.2.1 Preparation of Valsartan Form E 
14 g of valsartan powder (as received) was slurried in 100 mL of acetonitrile at 35 ⁰C for 24 h 
at 800 rpm. The resulting slurry was then filtered under vacuum; any remaining solvent was 
removed by drying in an oven at 40 ⁰C overnight at atmospheric pressure. 
2.2.2 Batch Process 
The experimental methods for the preparation and stabilization of valsartan, clozapine, 
carbamazepine and curcumin nanoparticles in suspension with the help of soluble excipient as 
well as their stabilization and isolation in solid state as dry powder with the help of  
montmorillonite ( MMT) or protamine functionalized montmorillonite (PA-MMT) carrier 
particles in a batch process are presented below. 
2.2.2.1 Preparation of API nanosuspensions stabilised with soluble excipients  
Nanosuspensions of the four APIs, valsartan (Val) clozapine (CLO), carbamazepine (CBMZ) 
and curcumin (CUR) were produced and stabilised via reverse liquid antisolvent precipitation 
by injecting the API dissolved in the appropriate organic solvent into water (the antisolvent) 
containing a suitable water-soluble polymer stabilizer (Pluronic® F-127, PVP K 30 or HPMC 
respectively). Process parameters such as solvent choice, antisolvent-solvent (AS/S) ratio 
(ranged from ~1:30 to ~1:70), choice and concentration of stabilizer in the antisolvent (ranged 
from 0.1% w/w to 0.4% w/w), the concentration of the API in the solvent (ranged from 20 
mg/ml to 100 mg/ml), were successfully optimized, thus allowing for good control over the 
particle size distribution of the respective API nanoparticles in suspension. All the experiments 
were carried out at 25 ⁰C under continuous stirring rate of 800 rpm. The optimized process 





Table 2.1: Optimized process parameters for producing polymer-stabilized nanosuspensions 
of valsartan, curcumin, clozapine and carbamazepine. 
API 
Volume and stabiliser 
concentration of 
antisolvent 
Dosing volume and 









20 mL of aqueous 
solution of Pluronic® F-
127 (0.2% w/w) 
0.5 mL of API 





20 mL of aqueous 
solution of PVP K 30 
(0.3% w/w) 
0.7 mL of API 





20 mL of aqueous 
solution of Pluronic® F-
127 (0.2% w/w) 
0.3 mL of API 





20 mL of aqueous 
solution of HPMC (0.4% 
w/w) 
0.3 mL of API 

















2.2.2.2 Preparation of API-MMT and API-PA-MMT nanocomposites 
API-MMT/API-PA-MMT nanocomposites of Val, CLO, CUR, and CBMZ were prepared and 
isolated by adapting reverse antisolvent precipitation in the presence of aqueous suspensions 
of MMT/PA-MMT carrier particles followed by simple vacuum filtration (Figure 2.11). In 
brief, API-MMT nanocomposites of Val, CLO, CUR and CBMZ were prepared by promptly 
injecting 0.5 mL of Val solution in methanol (100 mg/ml), 0.3 mL of CLO solution in methanol 
(50mg/mL), 0.7 mL of CUR solution in acetone (20mg/mL) or 0.3 mL of CBMZ solution in 
methanol (50mg/mL) respectively into 20 mL of an MMT suspension in water (containing 
different amounts of MMT ranging from 2.5 mg/mL to 10 mg/mL). API-PA-MMT 
nanocomposites of Val, CLO, and CUR were prepared by promptly injecting 0.5 mL of Val 
solution in methanol (100 mg/ml), 0.3 mL of CLO solution in methanol (50mg/mL) or 0.7 mL 
of CUR solution in acetone (20mg/mL) respectively into 20 mL of an MMT suspension (5 or 
2.5 mg/mL) in an aqueous solution of PA (containing different amounts of PA ranging from 0 
to 25 mg PA/g of MMT). All antisolvent compositions were equilibrated for 3 hrs at 25⁰C 
under continuous stirring of 800 rpm prior to injecting the API solution for reverse antisolvent 
precipitation. Following the reverse antisolvent precipitation, the resulting suspended API-
MMT or API-PA-MMT nanocomposites were aged for 1 min, then filtered using 0.2-micron 
polyvinylidene fluoride (PVDF) membrane filters. The resultant filter cakes were dried in a 
fume hood at ambient temperature and pressure for 24 hrs. 
The percentages of Val, CLO, CUR and CBMZ nanoparticles adsorbed onto the MMT or PA-
MMT carrier particles were determined by measuring the concentration of API in the filtrate 
on a Shimadzu UV-1800 spectrophotometer at λ= 250, 212, 424 and 284 nm respectively after 
diluting an aliquot of the filtrate by a factor of 10 in methanol (except for curcumin which was 





Figure 2.11. Production and isolation of API nanoparticles in the presence of (i) soluble 
stabilizers (upper path), and (ii) MMT or PA-MMT carrier particles (lower path). 
 
Nomenclature: Below a shorthand notation will be employed to describe the various APIs, 
Pluronic F127, Protamine (PA), and MMT formulations. For example, “Val-MMT-F127 NCs 
(9% w/w loading)” will refer to 9% valsartan loaded nanocomposites samples prepared in the 
presence of  MMT and Pluronic® F-127,  and “Val-PA-MMT NCs (33.3% w/w loading)” will 
refer to 33.3% valsartan loaded nanocomposites samples prepared in the presence of protamine 
(PA) modified MMT. This nomenclature applies to all API-MMT and API-PA-MMT 





2.2.3 Continuous Process 
The experimental methods for the preparation and stabilization of valsartan nanoparticles in 
suspension with the help of soluble excipient (Pluronic F-127) as well as their stabilization and 
isolation in solid state as dry powder with the help of  montmorillonite ( MMT) or protamine 
functionalized montmorillonite (PA-MMT) carrier particles in a continuous process are 
presented below. The model compound chosen for this study was valsartan (Val), as it was 
observed in our previous study that Val nanoparticles exhibits good stability when precipitated 
in batch mode with the help of soluble stabilizers or carrier particles. 
2.2.3.1 Apparatus and experimental procedure for the preparation of valsartan 
nanosuspensions using Pluronic F-127 as stabilizer in a continuous process 
Figure 2.12 shows the schematic set up for the continuous production of valsartan 
nanosuspension via the reverse antisolvent precipitation method. The system consists of two 
magnetic stirrers, a 60 mL jacketed reactor maintained at 250 C (precipitation chamber), which 
was initially filled with 60 mL of an aqueous solution of Pluronic F-127 (0.2% w/w), a one-
liter vessel that contains an aqueous solution of Pluronic F-127 (0.2% w/w), collection vials, a 




















Figure 2.12. A schematic illustration of the continuous preparation of a valsartan 
nanosuspension stabilized by Pluronic F-127.  
During the experiment, the aqueous solution of Pluronic F-127 (antisolvent) and the valsartan 
solution in methanol (solvent) were continuously pumped into the precipitation chamber at 
fixed flow rates of 50 mL/min and 1.13 mL/min, respectively, Figure 2.12. These flow rates 
were selected to achieve a drug-solution/anti-solvent ratio that would generate a particle size 
distribution of valsartan nanoparticles similar to that obtained via the batch processing. The 
working volume of the precipitation chamber was 60 mL, which was agitated (800 or 1200 
rpm) and overflowed continuously – the overflow was collected as discrete aliquots (60 mL) 
in a series of numbered vials, Figure 2.12. The ‘residence time’ (volume of precipitation 
chamber/total flow rate) of the continuously forming nanosuspension in the precipitation 
chamber was 60 mL / 51.13 mL.min-1 = 1.17 min. The overflow aliquots were collected 
continuously in series every 1.17 minutes such that each aliquot volume represented 1 nominal 
complete ‘residence time’ of the precipitation chamber (i.e. 60 mL). At the defined flow rates, 
and assuming complete precipitation of all available valsartan as it passed through the 
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precipitation chamber, the maximum attainable concentration of valsartan in the precipitation 
chamber was 2.21 mg/mL. 
2.2.3.2 Determination of steady-state conditions for the continuous antisolvent 
precipitation process 
The time required to achieve steady-state conditions for the continuous antisolvent 
precipitation process was defined as the time required to reach the maximum attainable 
concentration of valsartan (i.e. 2.21 mg/mL) in the precipitation chamber at the defined flow 
rates of solvent (drug solution) and antisolvent (aqueous solution of Pluronic F-127). It was 
determined by analyzing the concentration of valsartan in each aliquot volume (mg/mL) using 
a Shimadzu UV-1800 UV-Visible spectrophotometer (λ=250 nm) after firstly diluting the 
aliquot volume 40-fold in methanol. The process was deemed to have reached steady state once 
the valsartan concentration had reached its maximum attainable value (2.21 mg/mL in the 
precipitation chamber mixture) and had thereafter remained at a constant value, from one 

































2.2.3.3 Apparatus and experimental procedure for the preparation of Val-MMT and Val-
PA-MMT nanocomposites via continuous antisolvent precipitation 
The production of Val-MMT and Val-PA-MMT nanocomposites (NCs) via continuous 
antisolvent precipitation was achieved as per the process described in Section 2.2.3.1 except 
that the solution of PluronicF-127 was replaced by (i) aqueous suspensions of MMT of 
different concentrations (5 mg/mL to 25 mg/mL)  agitated at 800 rpm, or (ii) an MMT 
suspension (5 mg/mL) in an aqueous solution of PA (3 mg PA/g of MMT agitated at 800 rpm, 
and the collection vial was replaced by a simple Buchner filtration set up to isolate the Val-
MMT or Val-PA-MMT nanocomposites produced at 60 mL aliquot intervals as shown in 
Figure 2.13. The percentage of Val nanoparticles adsorbed onto MMT/PA-MMT carrier 
particles was determined by measuring the concentration of API in the filtrate on a Shimadzu 
UV- 1800 spectrophotometer (λ= 250 nm) by taking an aliquot of the filtrate and diluted by a 













Figure 2.13.  A schematic illustration of the preparation, stabilization by MMT, and isolation 





The greater productivity of the continuous method allowed a small number of tablets to be 
formulated and tabletted. Variously loaded dried Val-MMT nanocomposites solid were 
tabletted with a compaction simulator (Gamlen Tabletting D series) using a 6 mm round and 
flat-faced punch and die set. Two formulations were made; the first formulation contains only 
Val-MMT NCs while the second formulation comprised a blend of Val-MMT NCs and CMC 
(10%) as disintegrant. For each compression, 100 mg of sample  (100 mg Val-MMT NCs or 
100 mg sample containing 90% Val-MMT NCs and  10% CMC as disintegrant) was manually 
filled into the die and compacted by applying loads of 160-300 kg at a controlled upper punch 
velocity of 1 mm s-1. Load displacement data were used to calculate detachment and ejection 
stresses using in-die Heckle analysis. The tablet crushing force, hardness (F), thickness (h), 
diameter (D), and weight of the tablets produced were determined using a PTB 311E, pharm 
test hardness tester. The tablet tensile strength, σt (MPa), was calculated using Eq. (2.1) 211 




where F = hardness (N); h = tablet thickness (mm); D = tablet diameter (mm). 












2.2.4 Dissolution Studies 
2.2.4.1 In vitro API release studies 
In vitro dissolution profiles were obtained for (i) polymer-stabilised nanosuspensions of 
valsartan (Val), clozapine (CLO), curcumin (CUR) and carbamazepine (CBMZ), (ii) dry 
powdered samples of Val-MMT, Val-PA-MMT, CLO-MMT, CLO-PA-MMT, CUR-MMT, 
CUR-PA-MMT and CBMZ-MMT nanocomposites at different API loadings and with different 
degrees of PA functionalisation, and (iii) samples of  Val (Form E, particle size ~ 11 µm), CLO 
(as received, particle size ~ 11 µm), CUR (recrystallised, particle size ~ 6 µm) and CBMZ (as 
received, particle size ~ 16 µm). The dissolution studies were conducted under sink conditions 
in 100 mL of deionized water for Val, CLO and CBMZ, and 100 mL of an aqueous solution 
containing 0.3% SDS for CUR, under continuous agitation (300 rpm) at 37 ± 0.5⁰C. The extent 
of API dissolution of Val, CLO, CBMZ, and CUR was measured using a Shimadzu UV-1800 
spectrophotometer at λ= 250, 212, 284 and 424 nm respectively by withdrawing 1 mL aliquots 
at pre-determined time intervals (0.5, 1.5, 3, 5, 10, 15, 30 and 60 min) from the bulk solution 
with a preheated plastic syringe (~40 ⁰C, in order to avoid possibility of any crystallization 
while sampling for dissolution studies) and filtering through a 0.22 μm pore (in case of 
Val/CLO/CBMZ/CUR-MMT and Val/CLO/CUR-PA-MMT nanocomposites), 0.02 μm pore 
(in case of Val, CLO and CBMZ nanosuspensions) and 0.1 μm pore (in case of CUR 
nanosuspension) preheated polytetrafluoroethylene (PTFE) syringe filter. 
In vitro drug release studies of the tablet formulation of Val-MMT NCs and powdered 
formulation composed of a physical mix of Val-MMT NCs and CMC were carried out using 
USP compliant tablet dissolution type II (Pharma Test PTWS 120D) paddle apparatus. It was 
carried out under sink condition in 900 ml deionized water at 37 ± 0.5⁰C at a paddle rotation 
of 150 rpm. One mL aliquots were withdrawn at predetermined time intervals and the amount 
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of valsartan released was determined via UV-1800 UV-Visible spectrophotometer as described 
above. All measurements were carried out in triplicate. 
2.2.5 Dynamic Light Scattering (DLS) 
DLS also known as photon correlation spectroscopy (PCS) is used to determine the size of 
particle in suspension or polymers in solution typically in the nanometer range. DLS measures 
the Brownian motion of dispersed particles and relates them to its size. An important feature 
of Brownian motion in DLS is that smaller particles move quickly while larger particles move 
slowly. The relationship between a particle’s size and its speed due to Brownian motion is 
given by the Stokes-Einstein equation (Eq. 2.2)213. The diameter measured in DLS is referred 
to as the hydrodynamic diameter because it is calculated from the diffusional properties of the 






 where d(H)= hydrodynamic diameter, D= translational diffusion constant, k= Boltzmann 
constant, T= absolute temperature, and η= viscosity 
 When a small particle is illuminated by light the particle will scatter the light in all directions. 
This scattering light undergoes either constructive (same phase) or destructive (opposite phase) 
interference which causes bright or dark areas on the detector. As the suspended particle in a 
liquid is constantly in motion the intensity at a particular point appears to fluctuate. The 
Zetasizer nanosystem measures the rate of intensity fluctuation of scattered light by particles 
and uses this to calculate the size of the suspended particles.  
The particle size distribution of API nanoparticles was determined on a Malvern Zetasizer 
Nano ZSP system using water as the dispersion medium. The particle size distribution 
    (2.2) 
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measurements were performed using samples of the polymer-stabilised API nanosuspensions. 
All samples were equilibrated for 120 s prior to measurement, and all measurements were taken 
at 25⁰C. Refractive indices of 1.55, 1.681, 1.416, 1.669, and absorption indices of 0.1, 0.010, 
0.010, and 0.001 were used to measure the distributions of particle sizes and zeta potentials of 
the Val, CLO, CUR and CBMZ nanoparticles respectively. Particle size distributions were 
measured by utilizing a dynamic light scattering technique. Ten measurements were taken per 
run and each sample was run 3 times. The average D50 diameter and standard deviation were 















2.2.6 Zeta Potential   
Zeta potential is a scientific term for electrokinetic potential which is exhibited by any particles 
in suspension, macromolecules, or material surfaces. It is basically a potential difference 
between the dispersion medium and the stationary boundary within the diffuse region of fluid 
attached to the dispersed particle. When nanoparticles formed in the aqueous solution 
containing ions, counter-ions are attracted and co-ions are repelled. As a result, an electrical 
double layer exists around each particle, which consists of two parts, an inner region (Stern 
layer) where ions are strongly bound and an outer (diffuse) region where they are less firmly 
bound within which the particle acts as a single entity. When the particle moves (e.g. due to 
diffusion), ions within the boundary move with it, but any ions beyond the boundary do not 
travel with the particle. This boundary is called the surface hydrodynamic shear or slipping 








Figure 2.14. Illustration of the electric double layer around a particle in suspension along with 
their potential at each boundary. It consists of an inner region (Stern layer) where ions are 
strongly bound and an outer (diffuse) region where they are less firmly bound within which the 











Zeta potential is used to optimize suspensions, protein solutions and emulsions, optimize the 
formation of films and coatings and predict molecular interactions with surfaces. The zeta 
potential is the key indicator of the stability of a suspension and the best available methods of 
comparing the surface charge value of particles in a solution. Zetasizer nanosystem measures 
the zeta potential by determining the electrophoretic mobility (velocity of the particle in an 





Where, z is zeta potential, UE is electrophoretic mobility ϵ is dielectric constant f(ka) is Henry’s 
function, and η is Viscosity. Two values either 1.5 or 1 is generally used as an approximation 
for f(ka) determination. f(ka) is 1.5 in the case of aqueous media and referred to as 
Smoluchowski approximation214–216. For non-aqueous media f(ka) is 1 and referred to as the 
Huckel approximation214. 
Zeta potential analysis was carried out on a Malvern Zetasizer Nano ZSP system using water 
as the dispersion medium. The zeta potential measurements were performed using samples of 
free (that is, not polymer-stabilised) nanoparticles for each API; these free nanoparticles were 
generated via liquid antisolvent precipitation by injecting the API dissolved in the organic 
solvent into water (the antisolvent) and then conducting the zeta potential measurement as 
promptly as possible in order to minimize the extent of nanoparticle agglomeration. Refractive 
indices of 1.55, 1.681, 1.416, 1.669 and absorption indices of 0.1, 0.010, 0.010, and 0.001 were 
used to measure the zeta potential distribution of Val, CLO, CUR and CBMZ nanoparticles 
respectively. Zeta potentials of the nanoparticles were determined from electrophoretic 
mobility by using the Smoluchowski approximation214.  The samples were filled into disposable 
folded capillary cells and equilibrated for 120 s prior to measurement. Each measurement was 
taken at 25°C. Forty measurements were taken per run and each sample was run 10 times with 




a delay of 5 s between each run. The average Zeta potential and standard deviation were 
recorded for each sample. 
2.2.7 Morphology G3 particle size analysis 
The Morphology G3 is an automated particle imaging system that provides high-resolution 
direct measurement of size, shape, and other properties of powdered materials ranging from 
below one micron to several millimetres in size. It uses a digital camera to capture 2D images 
of a dispersed particulate sample. In this technique, each individual particle in the sample is 
measured one by one providing high-resolution detailed information. It is a very fast technique 
as it measures tens to hundreds of thousands of particles in the same amount of time needed to 
measure a very small number by manual microscopy. It is often used in combination with other 
particle characterization techniques to gain a deeper understanding of the materials.  
Number based particle size distributions of valsartan Form E, as received clozapine, as received 
carbamazepine, and recrystallized curcumin were measured using a Malvern Morphologi 
G3SE microscopic particle characterization system (Malvern Instruments, Malvern, UK). 
Powdered samples were dry dispersed using the system’s automated sample dispersion unit 
(SDU) with an area of 5541 mm2 onto a glass plate (180110 mm) with an injection pressure 
of 4.0 bar, an injection time of 10 ms and a setting time of 60 seconds. A diascopic light was 
passed from the bottom of the glass plate with automatic light calibration intensity using a set 
value of 80 and an intensity tolerance of 0.20. A range of particle sizes from 1µm-200µm was 





2.2.8 Solid state characterization 
2.2.8.1 Powder X-ray diffraction (PXRD) 
PXRD is a rapid and powerful analytical technique used to identify the phase of crystalline 
materials by measuring their powder diffraction patterns. Each phase produces unique 
diffraction patterns depending upon the crystal structure. Each polymorph, salt, cocrystal has 
its own specific diffraction pattern. X-ray diffraction is based on the elastic scattering of the X-
rays (electromagnetic radiation which travel in waves) by the atoms (more specifically 
electrons) in a periodic lattice. When the beam of X-rays interact with the sample, the incident 
beam is either reflected off the surface or can enter the lattice and diffracted by the atoms 
present in the sample.  If the atoms are arranged symmetrically with an interplanar distance d, 
these rays will interfere constructively when conditions satisfy Braggs’ Law (nλ=2d sin θ)217 
Figure 2.15.  
 






             
 





Constructive interference when: 
nλ=2dsin𝜃   
Bragg’s Law 




Here d is the interplanar distance, 𝜃 is the incident angle, λ is the wavelength of the X-ray 
source, and n is an integer. By scanning the samples through a range of 2𝜃, all the diffraction 
directions of the lattice can be attained. Each diffraction peak represents a particular lattice 
plane which is characterised by a Miller index (h k l). 
PXRD is used as a qualitative and sometimes quantitative assessment of crystalline materials. 
Qualitative analysis of PXRD is used to determine the phases present in crystalline materials 
by comparing the experimental PXRD data with the reference pattern, while quantitative 
analysis is used to calculate the percentage of each polymorph in a mix of polymorphs. It is 
widely used in the pharmaceutical industries to determine the phase of crystalline material, 
polymorphic forms, amorphous/crystalline content in a mixture, and crystal structure (Rietveld 
refinement). 
Reflection powder X-ray diffractograms (PXRDs) were recorded using an Empyrean 
diffractometer (PANalytical, Phillips) with Cu Kα1,2 radiation (λ = 1.5406 Å) operating at 40 
kV and 40 mA at room temperature. Samples were scanned from 5 to 50° (2θ) with 0.026° 












2.2.8.2 Differential scanning calorimetry (DSC) 
DSC is a thermal analytic technique used to measure the difference in the amount 
of heat required to increase the temperature of a sample cell (which contains a compound of 
interest) and reference cell (empty cell) as a function of temperature. The temperatures of both 
cells are maintained identically throughout the experiment. The basic principle underlying this 
technique is that the difference in energy required to match the temperature of the sample to 
that of the reference would be the amount of heat absorbed or released by the molecule in the 
sample during a physical transformation of the sample such as phase transitions. It provides 
qualitative and quantitative data on endothermic (heat absorbed by a sample e.g. melting) and 
exothermic (heat released by a sample e.g. crystallization) processes as a function of 
temperature. It is a very powerful technique used to evaluate material properties such as glass 
transition temperature, melting temperature, crystallization transition temperature, specific 
heat capacity, purity, thermal stability, etc. DSC is a widely used thermal technique in the 
pharmaceutical industry for accurately designing parameters for production which includes 
knowing the temperature at which undesirable phase changes will occur, for example, during 
the crystallization of drugs.  
DSC was carried out under a nitrogen environment (30 mL/min) using a PerkinElmer 
instruments Pyris 1 DSC in the range 30 to 170°C at scan rates of 10°C/min. Experiments were 
carried out using platinum pans with pinholes (as manufactured), sealed by a crimping press. 






2.2.8.3 Solid-state nuclear magnetic resonance (SSNMR) 
Nuclear magnetic resonance (NMR) spectroscopy is a chemical analytical technique used to 
observe local magnetic fields around atomic nuclei. It is the preeminent technique for 
determining the molecular structure of an organic compound by measuring the interaction of 
nuclear spins when placed in a strong magnetic field. The basic principle underlying this 
technique is that when the sample is placed in a magnetic field, the NMR signal is produced by 
excitation of the nuclei in the sample by applied radio waves into nuclear magnetic resonance 
which is detected with sensitive radio receivers. The intramolecular magnetic field around an 
atom in a molecule is affected by electron shielding which in turn depends upon the chemical 
environment that changes the resonance frequency. As a result, the chemical environment of 
the nucleus can be derived from its resonance frequency, thus giving access to details of the 
electronic structure of a molecule and its individual functional groups. Carbon-13 (13C) and 
proton (1H) are the most common type of NMR, but it is applicable to any kind of sample that 
contains nuclei possessing spin.    
Solution NMR (liquid NMR) requires compound to be dissolved in a deuterated solvent to 
obtain the NMR spectra of the corresponding compound. Contrary to solution NMR, Solid-
state NMR (SSNMR) does not require the solubilization of the compounds to be analyzed, thus 
preventing the loss of any feature intimately connected with its structure in the solid-state. 
SSNMR has established itself as a complementary technique to X-ray diffraction in the study 
of solid materials, especially in the case of APIs218–222. It can provide precious information 
about poorly crystalline or even amorphous samples223,224. Moreover, thanks to its high 
sensitivity to the local environment of the observed nuclei, SSNMR can be employed to probe 




The 13C SSNMR cross-polarization magic-angle spinning (CPMAS) spectra were obtained 
using a Bruker Avance III HD NMR spectrometer, operating at 400.23 and 100.63 MHz, 
respectively for 1H and 13C. Dry powdered valsartan nanocomposite samples were packed 
without further preparation into cylindrical zirconia rotors with a 4 mm o.d. and an 80 L 
volume. The 13C CPMAS spectra were acquired at room temperature at a spinning speed of 12 
kHz, using a ramp cross-polarization pulse sequence with a 90° 1H pulse of 3 s, a contact time 
of 3 ms, an optimized recycle delay of 3.14 s and a number of scans included in the range 400-
26900, depending on the sample. A two-pulse phase modulation (TPPM) decoupling scheme 
was used, with a radiofrequency field of 69.4 kHz. The 13C chemical shift scale was calibrated 

















2.2.9 Stability Testing 
2.2.9.1 Stability tests 
To investigate the stability of the nanocomposites over time, samples of Val-MMT and Val-
PA-MMT (all in the dry solid form obtained from batch experiments) were stored in closed 
glass vials on an open laboratory bench at room temperature for 10 months. After this time, the 
samples were analysed via DSC and PXRD, and in vitro drug release studies were also 
performed.   
2.2.9.2 Accelerated stability tests 
To investigate the stability of the nanocomposites over time, samples of Val-MMT and Val-
PA-MMT (all in dry solid form) were exposed to 40oC and 75% relative humidity for 2.5 
months in a desiccator (supersaturated solution of NaCl maintained at 40oC in a closed 
desiccator). After 2.5 months the samples were analysed via DSC, PXRD, SSNMR and in vitro 
drug release studies were also performed to determine whether the material had changed 
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Drug nanoparticles are a promising solution to the challenging issues of low dissolution rates 
and erratic bioavailability due to their greater surface area/volume ratio. The central purpose 
of this study is to prepare, stabilize and isolate nanoparticles of poorly water-soluble active 
pharmaceutical ingredients (APIs) into a dried form with the help of clay carrier particles. 
Isolation of nanoparticles from suspension into the dried state is crucial to avoid the problems 
of aggregation and Ostwald ripening. In this study nanoparticles of the API valsartan were 
generated via a reverse antisolvent process at high supersaturations. Montmorillonite (MMT) 
and protamine functionalized montmorillonite (PA-MMT) were employed for stabilization and 
isolation of the valsartan (Val) nanoparticles (ca. 50nm) into a dried form. A high dissolution 
rate of the resultant solid formulation at high drug loadings (up to 33.3 % w/w) was achieved. 
The dissolution rates of the isolated valsartan nanoparticle carrier composites (dried Val-MMT 
nanocomposites and dried Val-PA-MMT nanocomposites) were similar to that of freshly 
prepared suspended valsartan nanoparticles, confirming that the high surface area of the 
nanoparticles is retained during the adsorption and drying processes. Differential scanning 
calorimetry and PXRD studies indicated that the valsartan nanoparticles were amorphous when 
adsorbed onto the carrier particles. The dissolution rates of the Val-MMT and Val-PA-MMT 
nanocomposites were maintained after 10 months’ storage which indicates that no aggregation 







One of the greatest challenges in the pharmaceutical industry is to enhance the bioavailability 
of poorly water-soluble drugs. With respect to the Biopharmaceutics Classification System 
(BCS), approximately 40% of drugs currently in market fall into the category of either BCS 
class II (low solubility and high permeability) or BCS class IV (low solubility and low 
permeability)9,44,227. Drug solubility, dissolution, and gastrointestinal permeability are the key 
determinants of oral bioavailability 9,10. Thus, the bioavailability of these drugs is limited due 
to their low solubility and slow dissolution rates. Nanoparticle formulation strategies can help 
to address the problems of low solubility228 and slow dissolution rates90,228. They have proven 
to be highly successful due to the greater surface/volume ratio of nanoparticles, resulting in an 
improvement in dissolution rate and bioavailability as well as enhanced permeability229. 
Nanoparticles can be obtained either via a “top-down” approach or a “bottom-up” approach (as 
discussed in chapter 1 section 1.7). Although the “top down” approach is used for existing 
nanoparticle formulations on the market, it has limitations such as long processing times, high 
energy requirements, and the risk of contamination in the milling/homogenization chamber. It 
also tends to yield a broad particle size distribution229. On the other hand, the “bottom-up” 
approach, which includes liquid antisolvent precipitation, is fast, simple and cost-efficient 
technique126,168. However, nanoparticles in suspension are unstable, tending to agglomerate or 
to undergo Ostwald ripening48 to reduce their free energy47. One of the major challenges in 
stabilizing these nanoparticles in suspension lies in the identification of drug-specific crystal 
growth or aggregation inhibitors44 (soluble stabilizers). Isolation of nanoparticles from 
suspension to the dried state is crucial for their long-term stabilization and for the formulation 
of solid state oral drug delivery systems. Another major challenge in isolating these 
nanoparticles into the dried state is agglomeration during drying, again due to their high surface 
energy47. As summarized in section 1.8, current techniques used for isolating nanoparticles 
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from suspension to the dried state include spray drying, freeze-drying or centrifugation. These 
techniques can be  time-consuming, difficult to scale up and expensive, and can adversely affect 
the particle size distribution52,126,230.  
There are many reports available on the use of liquid antisolvent precipitation for the generation 
of nanoparticles44. Liquid antisolvent precipitation offers very high levels of supersaturation 
which promote nucleation over particle growth, and thus generate higher numbers of 
nanoparticles. However, there are few reports on the successful isolation of these nanoparticles 
in the solid state. As an alternative nanoparticles isolation strategy, Khan et al. first introduced 
the use of inert dibasic calcium phosphate as carrier particles for isolation of ibuprofen and 
glibenclamide nanocrystals162. However, the maximum drug loading on these carrier particles 
was very low, approximately 0.35% (w/w), which restricts its use to potent low-dose products 
162. We have previously reported a one-step approach for preparing, stabilizing and isolating 
the nanoparticles of two poorly water-soluble BCS class II drugs using montmorillonite 
(MMT) clay particles as carrier particles. These carrier particles serve the dual purpose of 
stabilizing the nanoparticles in suspension and thereafter allowing for their isolation via simple 
filtration into a dry powder form. In this previous study, fenofibrate and mefenamic acid 
nanoparticles (200-300nm) were isolated with MMT at 9.1 % and 4.8% w/w drug loadings 
respectively164. It was necessary to functionalize the surface of the MMT with protamine 
sulfate salt (PA), a polycationic peptide165  to prevent nanoparticle agglomeration at these 
loadings48. 
While MMT was observed to successfully act as a carrier particle for fenofibrate and 
mefenamic acid nanoparticles at loadings of less than 10 % w/w using PA as a surface 
functionalising group, the application of this PA-MMT composite as a generic carrier particle 
system for nanoparticles of other active pharmaceutical ingredients (APIs) of different 
chemistry and particle size has not been explored164. The dissolution rates of fenofibrate and 
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mefenamic acid from their respective PA-MMT nanocomposites were shown to be influenced 
by parameters such as nanoparticle size, degree of PA functionalization and drug loading on 
the carrier particle system, but the question remains as to whether these parameters are as 
relevant for smaller nanoparticles and other APIs. Therefore, this study aimed to compare the 
stability of API nanoparticles on MMT carrier particles in the presence and absence of soluble 
stabilizers and the surface functionalizing group PA, and explored if a combination of carrier 
particles and these additives has a synergistic or counteractive effect on the isolation capability 




















3.2.1 Particle size and particle size stability of the valsartan nanoparticles produced via 
reverse antisolvent precipitation 
Valsartan particles of 50 ± 0.4 nm were obtained in the presence of Pluronic® F-127 (as a 
soluble stabilizer of the drug particles) Figure 3.1. The particle size distributions of these 
nanoparticles remained stable in suspension over a period of 30 days when Pluronic® F-127 
was used (Figure 3.1).  
 
Figure 3.1. Particle size distributions of valsartan nanoparticles (50 nm) in nanosuspensions 
obtained following reverse antisolvent precipitation in the presence of Pluronic F 127 after 2 
min and after 30 days. 
However, when produced in the absence of Pluronic® F-127, the valsartan nanoparticles were 
observed to aggregate/grow from 50 nm initially to > 1 m after 30 minutes, Figure 3.2. The 
Pluronic® F-127 stabilized nanoparticles (50 nm) could not be isolated by simple filtration 
because they passed through or blocked the filter (0.22 µm pore size) due to their small size. 
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Hence, as outlined in the section immediately below, the MMT carrier particle system was used 
with the aim of stabilizing these nanoparticles in a solid form that was amenable to isolation 
via simple filtration. 
 
Figure 3.2. Change in the particle size distribution of valsartan nanoparticles in the absence 
of Pluronic® F-127 at different time intervals after precipitation from 2 to 45 minutes. 
3.2.2 Attachment of valsartan nanoparticles produced via reverse antisolvent 
precipitation to the MMT or PA-MMT carrier particles 
The attachment of the valsartan nanoparticles produced via reverse antisolvent precipitation 
onto the MMT or PA-MMT carrier particles was confirmed by the clear filtrate obtained after 
filtration of the related nanosupsensions through 0.22 µm PVDF membrane filters (Figure 3.3 
– lower path). The concentration of drug in the filtrate was measured by UV Shimadzu UV-
1800 UV-Visible spectrophotometer (λ=250 nm) by taking an aliquot of the filtrate and diluting 
by a factor of 10 in methanol to dissolve any drug particles present prior to measurement. This 
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confirmed that > 99% of the valsartan present had adsorbed onto the MMT or PA-MMT carrier. 
Stabilized nanosuspensions filtered in the absence of MMT carrier particles passed through the 
0.22 µm PVDF membrane filter resulting in a milky filtrate (Figure 3.3 – upper path). When 
the antisolvent precipitation was conducted in the presence of the MMT or PA-MMT carrier 
particles, almost complete (>99%) adsorption of the valsartan nanoparticles at a maximum drug 
loading of 33.3% w/w was achieved without the need to include  Pluronic® F-127 as a soluble 
stabilizer. The percentage recovery of nanoparticles onto MMT or PA-MMT carrier particles 
decreased from 99% to 88% when the valsartan loading was increased from 33.3% to 40% 
w/w. 
Figure 3.3. Production and isolation of valsartan nanoparticles in the presence of (i) 
Pluronic® F-127 (upper path), and (ii) MMT or PA-MMT carrier particles (lower path). 
For nanocomposites formed with MMT and Pluronic® F-127, and at valsartan nanoparticle 
loadings greater than 9.1%, there was a pronounced decrease in the percentage recovery of 
nanoparticles and a milky filtrate was obtained. It was also found that the surface charge of 
MMT increased from -30.7 ± 0.14 to -0.08 ± 0.01 mV when MMT was incubated with F127 
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(Figure 3.12). Thus, the presence of Pluronic® F-127 reduced the MMT’s effectiveness at 
isolating the nanoparticles.  
3.2.3 Dissolution behavior of the variously prepared nanodrug-carrier composites 
After filtration and drying, the variously prepared dried nanodrug-carrier composites (hereafter 
referred to as nanocomposites (NCs)) were suspended in de-ionised water and the related 
dissolution profiles of valsartan were measured. The results are presented in Figure 3.4 for 
samples with valsartan loadings in the range 9 to 33.3 % w/w. For comparison purposes, this 
figure also includes the dissolution profiles for (i) Valsartan Form E (particle size ~11µm) and 
(ii) 50 nm valsartan particles from a freshly prepared stabilized nanosuspension. The first 
observation is that all NCs samples (whether prepared in the presence or absence of Pluronic® 
F-127) exhibited a more desirable valsartan dissolution profile than that of valsartan Form E, 
Figure 3.4 (a) and (b). For NCs samples prepared in the presence of Pluronic® F-127, the 
dissolution profile for valsartan from 9% w/w loaded dried Val-MMT-F127 was comparable 
with that of the freshly prepared valsartan 50 nm nanosuspension, although this comparison 
became less favourable as the valsartan loading increased to ca. 14 % w/w and above. By 
contrast, the dissolution profiles for valsartan from dried Val-MMT NCs samples prepared in 
the absence of Pluronic® F-127 were comparable with that of the valsartan 50 nm 
nanosuspension for drug loadings up to 20% w/w.  The trend in terms of loading and dissolution 
rate is not consistent in the range of 9–20% w/w loading but the release profiles are comparable. 
However, above 20% w/w, a distinct reduction in the rate of release is observed when the 
loading was increased to 33% w/w.  
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Figure 3.4. Comparison of the dissolution profile for valsartan Form E with those for valsartan 
from the following formulations in de-ionised water at 37oC: (a) valsartan nanosuspension, 
and dried Val-MMT nanocomposites (NCs) with different valsartan loadings (% w/w), and (b) 





The particle size of the drug in the Val-MMT-F127 (9% w/w valsartan) and the Val-MMT (20 
% w/w valsartan) nanocomposite samples can be considered broadly similar to that of the drug 
nanoparticles in the nanosuspension (50 nm) because of the comparable dissolution profiles 
amongst all three samples; this indicates that both of these NC formulations likely possess 
similar available surface areas for dissolution up to the stated valsartan loadings. The somewhat 
poorer valsartan dissolution profiles observed for the NC samples above these stated loadings 
may be due to aggregation of the drug nanoparticles prior to or after their addition to the carrier 
particle suspensions. 
In one series of experiments, valsartan nanoparticles were prepared via reverse antisolvent 
precipitation in the presence of the stabilizer Pluronic® F-127 but MMT was only added after 
the precipitation of the valsartan was complete. In this experiment, the valsartan loading was 
9.09 % w/w. Figure 3.5 compares the corresponding dissolution profile for valsartan from the 
resultant dried Val-MMT-F127 nanocomposite with that for the valsartan 50 nm 
nanosuspension. The very similar dissolution profiles for both samples is consistent with a 
mechanism whereby valsartan precipitates at the high supersaturations generated during the 
reverse antisolvent process to form nanoparticles stabilized by the Pluronic® F-127 which then 






Figure 3.5. Comparison of the dissolution profile for valsartan Form E in de-ionised water at 
37oC with those for the following formulations: (i) valsartan nanosuspension and (ii) dried 
Val-MMT-Pluronic® F-127 nanocomposite (NCs) at 9.09% w/w valsartan loading prepared 
via the addition of MMT after the reverse antisolvent precipitation of the valsartan 
nanoparticles.  
3.2.4 Charge modification of MMT with PA 
The relative disimprovement in valsartan’s dissolution profile from the dried Val-MMT 
nanocomposite at 33.3 % w/w loading likely indicates that some aggregation of the valsartan 
nanoparticles was occurring on the surface of the carrier particles. Therefore, to improve the 
dissolution profile at this higher drug loading, the surface charge properties of the MMT carrier 
particles were modified by the adsorption of Protamine (PA) prior to the reverse antisolvent 
precipitation step. In a previous study, using MMT with a PA surface coverage of 4.6 mg/g 
during the reverse antisolvent precipitation of fenofibrate and mefenamic acid proved effective 
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in enhancing these APIs’ dissolution profiles from their respective API-PA-MMT 
nanocomposites164.  
The zeta potentials of freshly prepared valsartan nanoparticles, the Val-MMT nanocomposite 
(9.09% w/w loading) and unmodified MMT were measured to be -42.5 ± 1.37 mV, -29.2 ± 
1.41 mV and -30.7 ± 0.14 mV respectively in aqueous media. After the adsorption of varying 
amounts of PA from 2 to 25 mg/g of MMT, the surface charge of the PA-MMT particles 
changed from -30.1 ± 0.40 to 16.9 ± 0.25 mV Figure 3.6. 
  
Figure 3.6. Zeta potential distributions for PA-MMT at various PA surfaces coverages from 






The zeta potential of the carrier was dependent on the coating density of PA on the MMT 
surface and was easily tuned by varying the levels of adsorbed PA Figure 3.7.  
 
Figure 3.7. The influence of varying levels of adsorbed PA (in mg/g MMT) on the zeta potential 










The PA-MMT carrier particles also adsorbed over 99% of the valsartan nanoparticles at the 
maximum drug loading of 33.3% w/w in the absence of Pluronic® F-127. The dissolution 
profiles of valsartan from Val-PA-MMT (33.3% w/w loading) with different surface coverages 
of PA are shown in Figure 3.8. 
 
Figure 3.8. Dissolution profiles of Val-PA-MMT nanocomposites (each 33.3% w/w loading) 
at various PA-MMT coverages. 
3 mg/g of MMT at a 33.3 % w/w valsartan loading was found to be the optimum PA coverage 
to give a dissolution profile that was comparable with that of a freshly prepared valsartan 50 
nm nanosuspension. This is a much higher API loading than the previously reported 9.1 and 





The effect of PA loading on valsartan’s initial dissolution rate from the resultant series of Val-
PA-MMT nanocomposites (0 – 25 mg/g MMT) is shown in Figure 3.9. 
 
Figure 3.9. The variation in the initial dissolution rate of valsartan from 33.3% w/w loaded 
Val-PA-MMT nanocomposites characterized by different zeta potentials arising from the 
indicated surface coverages of PA in mg/g of MMT. The initial dissolution rate is defined as 
the % of the available valsartan dissolved in the first 30 seconds of contact with the dissolution 
medium.  
3.2.5 Stability of Val-MMT and Val-PA-MMT nanocomposites 
After storage for ten months at ambient temperature, Val-MMT and Val-PA-MMT 
nanocomposites displayed valsartan dissolution profiles (Figure 3.10) comparable with those 
of freshly prepared Val-MMT and Val-PA-MMT nanocomposites. This suggests that no 
recrystallization/aggregation of the valsartan nanoparticles has occurred during this time, 
indicating the long-term stability potential of Val-MMT and Val-PA-MMT nanocomposites. 
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Figure 3.10. Comparison of the valsartan dissolution profiles of (a) freshly prepared dried 
Val-MMT nanocomposites with 10 month old Val-MMT nanocomposites, and (b) freshly 






3.2.6 Solid state characterization 
The powder XRD pattern of unprocessed valsartan Form E showed characteristic high intensity 
diffraction peaks, as did the pattern for a 33.3 % w/w physical mixture of Val Form E and 
MMT, Figure 3.11 (a). However, no characteristic diffraction peaks were observed in any of 
a selection of variously loaded Val-MMT nanocomposites, suggesting that the drug 
nanoparticles therein were X-ray amorphous.  
DSC analysis was therefore undertaken to further investigate the physical state of the valsartan 
nanoparticles adsorbed onto the MMT carrier particles. The thermogram of unprocessed 
valsartan Form E showed an endothermic peak at 138.4 ± 0.4⁰C corresponding to its melting 
temperature, while the corresponding thermogram of its 33.3 % w/w physical mixture with 
MMT gave a similar profile. However, the melting peak of valsartan was not detected in any 
of the thermograms of a selection of variously loaded Val-MMT and Val-PA-MMT 
nanocomposite samples; these included a 33.3% w/w loaded sample which had been stored at 
room temperature for 10 months, suggesting that the adsorbed valsartan nanoparticles had not 



















Figure 3.11. (a) PXRD patterns of valsartan Form E (experimental and from the CSD), a 
33.3% w/w physical mixture of valsartan and MMT, MMT, and a selection of valsartan 
nanoparticle-MMT composites with different valsartan loadings (%w/w), and (b) DSC profiles 
of valsartan Form E, a 33.3% w/w physical mixture of valsartan and MMT, a selection of 
valsartan nanoparticle-MMT composites with different valsartan loadings (%w/w) including a 
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Carrier particle mediated isolation of nanoparticles is a very straightforward and facile method 
to stabilize and isolate nanoparticles using simple filtration and drying. Drug nanoparticle 
loading depends upon several factors such as the accessible surface area, size and surface 
charge of the carrier particles, functional group complementarity, and nanoparticle-carrier 
particle interactions231. In this study valsartan nanoparticles formed by reverse antisolvent 
precipitation at high supersaturations attach to MMT and PA-MMT carrier particles. The 
resulting Val-MMT and Val-PA-MMT nanocomposites can be isolated from the suspension as 
stable solids by simple filtration followed by air-drying. In all cases studied, almost complete 
adsorption (>99%) of valsartan nanoparticles to MMT or PA-MMT carriers was observed 
irrespective of these carrier particles’ zeta potentials.  From this study, it has been shown that 
the PA-MMT carrier particle system facilitates the isolation of valsartan nanoparticles for drug 
loadings up to 33.3 % w/w while maintaining valsartan dissolution profiles comparable with 
that of freshly prepared valsartan nanosuspensions (50 nm). This loading is over three times 
higher than that previously achieved during the earlier related study with fenofibrate and 
mefenamic acid164. A significant disimprovement in valsartan’s percentage recovery and 
dissolution profile (above 9.09% w/w loading) was observed for valsartan nanocomposites 
formed with MMT and Pluronic® F 127, instead of with MMT or MMT treated with PA alone. 
Thus, a negative influence on valsartan’s isolation and dissolution profile is observed in the 
presence of the soluble stabilizer Pluronic® F 127. This might be due to the inadvertent 
interaction of Pluronic® F 127 with MMT to form a polymer-clay composite whose surface 
area is then less receptive to adsorbing valsartan nanoparticles232,233. This hypothesis is 
supported by the observed change in MMT’s zeta potential from -30.7 to -0.08 mV (Figure 
3.12) following its suspension in a solution of Pluronic® F 127; this is likely due to the latter’s 
adsorption onto the MMT’s outer surface.    
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Figure 3.12. Zeta potential distributions for MMT and MMT-Pluronic® F-127 composites. 
There have been several reports of drug intercalation in MMT whereby drug molecules have 
been adsorbed into the interlayers of MMT clays201,234–238. However, the valsartan 
nanoparticles produced during this study are much larger in size (50 nm) than the distance 
between the layers of MMT (0.9 to 1.2 nm), thus restricting their adsorption onto MMT’s outer 
surface. As such, the valsartan nanoparticles’ predominant surface residency likely contributed 
to the drug’s prompt dissolution from the Val-MMT and Val-PA-MMT nanocomposites. Both 
types of valsartan nanocomposites exhibited excellent dissolution rates, with more than 90% 
of drug dissolving in less than 10 minutes. This compares favorably with the dissolution 
profiles for a number of other intercalated drug-MMT composites aforementioned27-32. For 
example, Joshi et al. have reported that less than 50% of timolol maleate dissolved after 8 h 
from a sample of the drug intercalated in MMT201. The surface of MMT is characterized by 
protrusions of polar hydroxyl groups (–OH) and hydrophobic siloxane groups (Si–O–Si), 
leaving it negatively charged due to the absence of nearby isomorphic cation substitution207–209 
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The negative charge is compensated by exchangeable cations (Na+, K+, Ca2+, etc.) usually in 
hydrated form located at the external surface while majority being present in the interlayers210. 
However, despite also being negatively charged, the valsartan nanoparticles still adsorb onto 
the negatively charged MMT carrier particles. Adsorption is therefore potentially due to 
electrostatic interaction between the +ve charged sites (due to presence of exchangeable 
cations) on the MMT clay surface or due to hydrophobic interactions between the aliphatic 
and/or aromatic groups of valsartan and the siloxane groups239 present on the MMT 
surface200,208,209.  
Drug dissolution profiles comparable with that for valsartan nanosuspensions (50nm) were 
obtained at Val-MMT drug loadings of up to 20% w/w. Above this loading, and when in the 
absence of PA, the valsartan nanoparticles started aggregating on MMT’s surface, which 
adversely impacted their ability to dissolve. However, with the help of PA to reduce the 
unfavourable interactions between MMT and the valsartan nanoparticles, dissolution profiles 
comparable with that of the nanosuspension were maintained up to a drug loading of 33.3% 
w/w. These findings compare favourably with those from our earlier related study on 
fenofibrate where such dissolution-hindering aggregation occurred at a much lower drug 
loading of 9.1 % w/w. This difference in aggregation/dissolution profiles may simply be due 
to the larger particle size of fenofibrate’s isolated nanoparticles (200 to 300 nm diameter) 
relative to that of valsartan’s (50 nm diameter), whereby the impact of even moderate levels of 
nanoparticle aggregation would likely be more pronounced in the case of the larger fenofibrate 
nanoparticles. Furthermore, MMT does not present a smooth surface, and the smaller valsartan 
nanoparticles may have comparatively better access than the larger fenofibrate particles to the 
MMT surface which is rich in terraces and pores. Thus, the capacity of MMT to accommodate 
more nanoparticles of a smaller size may account for the higher stabilization capacity of MMT 
for valsartan over fenofibrate. 
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Clearly, the introduction of charged adsorption sites on the MMT surface proved beneficial in 
limiting the formation of drug nanoparticle aggregates in favour of a more homogeneous 
segregation of the nanoparticles on the carrier particles. This was done by modifying the charge 
on the MMT carrier particles using positively charged PA164, and the extent of PA’s coating 
density was seen to greatly influence valsartan’s initial dissolution rate from 33.3% w/w Val-
PA-MMT nanocomposites.  This may be inferred from Figure 3.9 where optimum dissolution 
coincided with a carrier particle zeta potential of -27.7 mV (at 3 mg of PA/g of MMT) versus 
ca. -40 mV for the valsartan nanoparticles. In this study, and those previously undertaken for 
fenofibrate and mefenamic acid164, the optimal PA coverage on MMT was between 3 and 5 
mg/g MMT, and PA-MMT carrier particles have been shown capable of acting as a generic 
stabilizer and nano-isolator for all three APIs. The zeta potentials of the three APIs are similar 
(-30 to -40 mV)164,which may explain the similar optimal surface coverage of PA among them. 
In all three cases studied, this rather sparse coating of PA on MMT appears enough to introduce 
a sufficient number of favourable adsorption sites on MMT’s surface for the homogeneous 
segregation of drug nanoparticles to occur, thus producing such promising initial dissolution 
rates. 
MMT has net negative charge. Therefore, its surface will become less negatively charged as 
evermore PA is introduced. However, at higher PA coating densities, a negative impact on 
valsartan’s dissolution profile was seen. This was due to the accumulation of positively charge 
PA on MMT’s surface, around which the valsartan nanoparticles clustered, leading to 
aggregation. Conversely, valsartan’s dissolution profile also suffered at lower PA coating 
densities, indicating that the nanoparticles were most likely aggregating on the MMT’s surface 
due to presence of insufficient favourable adsorption sites for homogeneous segregation. The 
PA-MMT zeta potential of -25 to -28 mV seems to represent an optimum range whereby the 
valsartan nanoparticles can attach to PA-MMT in a manner which minimized aggregation. 
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Further studies are being conducted to establish whether API nanoparticles with different zeta 





























In summary, nanoparticles of valsartan (50 nm) have been prepared, stabilized and isolated on 
protamine-functionalized MMT carrier particles in a dried form, with a high dissolution rate at 
high drug loadings (33.3 % w/w) and exhibiting long-term stability. PA-MMT can thus act as 
a generic carrier particle system to enable the stabilization and isolation of API nanoparticles 
following their reverse antisolvent precipitation from solution. For API nanoparticles with a 
zeta potential in the range of -30 to -40 mV, it appears that a PA surface coverage of 3 to 5 
mg/g MMT helps to limit the extent of nanoparticle aggregation and thus enhance the API’s 
dissolution profile. From this study it has been found that smaller nanoparticles enable higher 
drug loadings without any decrease in dissolution rate. The high drug nanoparticle loading 
obtained in this study offers a potentially effective means of formulating relatively potent low-
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Nanoparticles (NPs) of three poorly water-soluble active pharmaceutical ingredients (APIs) 
(clozapine (CLO), curcumin (CUR) and carbamazepine (CBMZ) with zeta potentials -28.5 
±2.5, -33±1.5 and -13±1.5 mV respectively) were produced, stabilised and isolated into the 
solid state with the help of Montmorillonite (MMT) clay carrier particles. The nanoparticles of 
clozapine (27nm), curcumin (170 nm) and carbamazepine (30 nm) were produced and 
stabilized in suspension using a reverse antisolvent precipitation technique in the presence of 
‘as received’ MMT carrier particles (~30 m) and/or MMT carrier particles whose surface had 
been slightly modified with a cationic protein, protamine sulphate salt (PA). The resulting 
nanoparticle carrier composites were isolated directly from suspension into a solid state form 
by simple filtration followed by air-drying. The API dissolution rates from these dried NP-
carrier composites were comparable with those of the respective stabilized API nanoparticles 
in suspension up to maximum CLO, CUR and CBMZ loadings of 23%, 21.8% and 33.3 % w/w 
respectively, although surface modification of the MMT carrier particles with PA was needed 
for the CLO and CUR NP-carrier composites in order to preserve the fast API nanosuspension-
like dissolution rates at higher API loadings. For both of these APIs, the optimal loading of PA 
on MMT was around 4 mg/g, which likely helped to limit the aggregation of the API 
nanoparticles at the higher API loadings. Interestingly, no MMT surface modification was 
needed to preserve fast API dissolution rates at higher API loadings in the case of the CBMZ 
NP-carrier composites. This discrimination among the three APIs for carrier particle surface 
modification was previously observed in reported studies by our group for three other APIs, 
namely valsartan, fenofibrate and dalcetrapib. When examined together, the data for all six 
APIs suggest a general trend whereby API nanoparticles with zeta potentials more positive than 
around -25 mV do not require carrier particle surface modification with PA in order to preserve 
their fast dissolution rates from NP-carrier composites at higher API loadings.  
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Thus, this study offers a potentially effective means of transforming poorly water-soluble APIs 
into fast dissolving solid dosage NP-carrier composites, whereby the surface properties of the 



















Chapter 3 discussed the successful preparation, stabilization and isolation of valsartan 
nanoparticles (50 nm), with the help of montmorillonite (MMT) or protamine functionalized 
montmorillonite (PA-MMT) carrier particles, into a dried solid state form that displayed a fast 
dissolution rate at high drug loadings (33.3 % w/w) and exhibited long-term stability. Our 
group has also undertaken the preparation, stabilization and isolation of nanoparticles of 
fenofibrate164, dalcetrapib240 and mefenamic acid164 into the solid state with the help of MMT 
or PA-MMT carrier particles, achieving excellent dissolution rates at API loadings of 9.1%, 
20.9% and 4.8% (w/w) respectively. Nanoparticles of these APIs were generated in suspension 
via antisolvent precipitation, and carrier particle-mediated stabilization and isolation of these 
nanoparticles from suspension into a solid form was achieved by adding the carrier particles 
before or shortly after precipitation, followed by simple filtration and air drying. The 
dissolution rates of these APIs from their respective MMT or PA-MMT nanocomposite solids 
were shown to be influenced by parameters such as nanoparticle size, the extent of PA 
functionalization and the API loading on the carrier particle system164,241. 
The challenge associated with the MMT stabilized nanoparticles is one of achieving a high API 
loading while maintaining the integrity, stability and excellent dissolution properties of the 
nanoparticles. The “API loading” in commercially available tablet/capsules (that is, the mass 
of API as a percentage of the total tablet mass: % w/w) depends upon several factors such as 
the dose required, the choice of excipients and the API properties in terms of the chemical and 
physical interference with the excipients. A review of the commercially available 
nanoformulations of Emend and Triglide indicates API loadings of approximately 25-30% 
w/w, while the loading in Zanflex is 3-5% w/w. In our published work to date the highest API 
loading achieved has been 33.3% w/w for valsartan on PA-MMT (chapter 3), while much 
lower values (in the range 4-9% w/w) were achieved with fenofibrate and mefenamic acid. A 
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reasonable interim objective for these API nanocomposites would be 30% w/w while still 
maintaining fast dissolution properties, although ultimately the target loading depends on the 
potency and required dose of each particular API.  
In light of the above, the study described in this chapter focused on investigating the effect of 
protamine in modifying the zeta potential of MMT and how this modification influences the 
ability of the clay to stabilize API nanoparticles with different zeta potentials at high loadings. 
A panel of API nanoparticles with different zeta potentials (clozapine (CLO), carbamazepine 
(CBMZ) and curcumin (CUR) – Figure 4.1) was screened to examine the role of PA in 
extending their maximum API loading when present in nanocomposites while maintaining the 
dissolution behavior of these nanoparticles. In the discussion section of this chapter (section 
4.3), data from our previous studies related to fenofibrate164, mefenamic acid164, dalcetrapib240 
and valsartan (Chapter 3) will also be incorporated. 
 




4.2.1 Particle size distributions of the polymer-stabilised API nanoparticles 
Using the optimized process parameters shown in Table 2.1 (section 2.2.2.1), nanoparticles of 
CLO, CUR and CBMZ with particle sizes of 27±0.5, 173±0.8 and 30±0.5 nm respectively were 
obtained immediately after their precipitation from their supersaturated solutions in the 
presence of soluble polymeric stabilizers, Pluronic® F-127, PVP K 30 and HPMC respectively 
(Figure 4.2) 
 
Figure 4.2. Particle size distributions and average particle size (immediately after 
precipitation) of clozapine (CLO), curcumin (CUR) and carbamazepine (CBMZ) nanoparticles 
in suspensions obtained following reverse antisolvent precipitation in the presence of 




It was not necessary to use soluble stabilizers while making API-MMT and API-PA-MMT 
nanocomposites (section 2.2.2.2) because the nanoparticles adsorbed onto the MMT carrier 
particles immediately after precipitation. It appears that the MMT and PA-MMT carrier 
particles alone were able to stabilize the nanoparticle size and surface area (as indicated by the 
subsequent fast API dissolution rates for the API-MMT and API-PA-MMT nanoparticle-
carrier composites, section 4.2.3). 
4.2.2 Attachment of API nanoparticles onto MMT / PA-MMT carrier particles 
Attachment of API nanoparticles onto the MMT / PA-MMT carrier particles was confirmed by 
the clear filtrate obtained following filtration (through 0.22 μm PVDF membrane filters) of the 
respective API nanocomposite suspensions, and thereafter by checking the API concentration 
in the filtrates by UV-Vis spectroscopy. The concentration of API in the filtrate confirmed that 
>99% of the CLO, CUR and CBMZ had adsorbed onto the MMT / PA-MMT carrier particles 
at loadings of 9.09%, 21.8% and 33.3% w/w respectively. The extent to which CLO, CUR and 
CBMZ nanoparticles adsorbed onto the MMT / PA-MMT carrier particles reduced to 87.4%, 
81.8% and 88% when the CLO, CUR and CBMZ loading was increased to 23%, 31.8% and 
42.8% w/w respectively (Figure 4.3) 
The functionalisation of MMT with PA does not seem to effect the amount of API which can 




Figure 4.3. Percentage attachment of CBMZ, CUR and CLO nanoparticles onto MMT () or 
PA-MMT () carrier particles at various loadings (% w/w). 
4.2.3 Dissolution studies of API-MMT nanocomposites 
The dried API-MMT nanocomposite solids of CLO, CUR and CBMZ were suspended in 
deionized water at 37 °C and their API dissolution profiles were established. Figure 4.4 
compares the dissolution profiles of the three APIs from their respective API-MMT 
nanocomposites with the dissolution profiles of the APIs for (i) their respective crystalline 
forms, and (ii) their respective polymer-stabilised nanosuspensions. The dissolution profiles 
for all three APIs from their respective MMT nanocomposite solids were considerably better 
than the profiles for their respective crystalline forms in terms of the rate of API dissolved. 
Furthermore, the dissolution profile for CUR and CLO from the 9% and 6.5% w/w loaded 
CUR-MMT and CLO-MMT nanocomposite solids respectively were similar to the profiles for 
their polymer-stabilized nanoparticles in suspension. The comparison becomes less favourable 
at higher loadings for both APIs (Figure 4.4 (a) and (b)). By contrast, the dissolution profiles 
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for CBMZ from CBMZ-MMT nanocomposite solids up to an API loading of 33.3% w/w were 










Figure 4.4. Comparison of the dissolution profiles in de-ionized water at 37oC for (a) curcumin 
(CUR) as received (~6 µm) with those for curcumin from the following formulations: PVP K 
30-stabilized curcumin nanosuspension and dried CUR-MMT nanocomposites (NCs) with the 
indicated curcumin loadings (w/w %), (b) clozapine (CLO) as received (~11 µm) with those 
for clozapine from the following formulations: Pluronic® F-127-stabilized CLO 
nanosuspension and dried CLO-MMT nanocomposites (NCs) with the indicated clozapine 
loadings (% w/w), and (c) carbamazepine (CBMZ) as received (~16 µm) with those for 
carbamazepine from the following formulations: HPMC-stabilized carbamazepine 
nanosuspension and dried CBMZ-MMT nanocomposites (NCs) with the indicated 







4.2.4 Charge Modification of MMT with PA 
There was a noticeable deterioration in the API dissolution profiles for CUR-MMT and CLO-
MMT nanocomposites at higher API loadings of 21.8% and 23 % (w/w) respectively. This may 
be due to aggregation of the API nanoparticles on the MMT surface resulting in less available 
nanoparticle surface area for dissolution. In order to improve the dissolution rate of CUR and 
CLO at higher loadings, the surface charge of MMT was modified by the adsorption of the 
cationic protein protamine (PA) prior to the antisolvent precipitation step by following the 
procedure outlined in the previous studies from our group164,241 (section 2.2.2.2).  
In these previous studies, a loading of PA on MMT of around 3-5 mg/g was found to be 
optimum for maintaining nanosuspension-like dissolution profiles for valsartan (Val), 
fenofibrate (FF) and mefenamic acid (MEF) nanoparticles at higher loadings from Val-PA-
MMT(chapter 3, section 3.2.4), FF-PA-MMT164 and MEF-PA-MMT164 nanocomposites 
respectively, possibly due to the PA’s ability to reduce the extent to which the API 
nanoparticles aggregated on the MMT’s surface. 
Free nanoparticles of CLO, CUR and CBMZ possess negative zeta potentials of -28.5±2.5, -
33±1.5 and -13±1.5 mV respectively (Figure 4.5). Unmodified MMT also possesses a negative 
zeta potential of -31±1 mV, which can be tuned from negative to positive by adsorption of 










Figure 4.5. Zeta potential distributions of suspensions of (a) Curcumin (-33±1.5 mV), (b) 
Clozapine (-28.5±2.5 mV) and (c) Carbamazepine (-13±1.5 mV) nanoparticles immediately 
after precipitation 
In the case of CLO-MMT nanocomposites, the maximum loading at which a nanosuspension-
like dissolution profile was preserved was 6.5% w/w when the MMT was not functionalized 
with PA. However, having functionalizing the MMT with  PA prior to antisolvent precipitation, 
the maximum loading at which a nanosuspension-like dissolution profile was preserved for 
CLO-PA-MMT nanocomposites increased to 23% w/w (Figure 4.6 (a)). Similarly for the 
curcumin system, by functionalizing MMT with PA, the loading of CUR at which a 
nanosuspension-like dissolution profile could be preserved increased from 9% to 21.8% w/w 
(Figure 4.6 (b)). By contrast, the dissolution profile for CBMZ from CBMZ-MMT 
nanocomposites at loadings up to 33.3% w/w was already comparable with that for 
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carbamazepine from its polymer-stabilised nanosuspension (Figure 4.4 (c)), and modification 










Figure 4.6. Comparison of the dissolution profiles in de-ionized water at 37oC of (a) clozapine 
(CLO) from the following formulations: Pluronic® F-127-stabilized CLO nanosuspension, 
dried CLO-MMT nanocomposite (NC) (23% w/w) and dried CLO-PA-MMT nanocomposites 
(23% w/w) at different PA coverages, and (b) curcumin (CUR) from the following 
formulations: PVP K 30-stabilized curcumin nanosuspension, dried CUR-MMT 
nanocomposite (NCs) (21.8% w/w) and dried CUR-PA-MMT nanocomposites (21.8% w/w ) at 









The optimal PA coverage on MMT in both cases (CLO and CUR) was 4.2 mg PA/g of MMT 
(Figure 4.6). The zeta potential of PA-MMT at this coverage was -29±0.7 mV, while the zeta 
potentials at coverages of 5.8 and 6.36 mg of PA/g of MMT were -27.3±0.4 and -26±0.7mV 
respectively (Figure 4.7). Thus, only a very small change in zeta potential (-31±1 mV to -
29±0.7 mV) of MMT is required to preserve the API nanosuspension-like dissolution rates at 
higher loadings. 
 
Figure 4.7. Zeta potential distributions of MMT (-31±1 mV) and PA-MMT at the following 
PA coverages: 4.2 mg of PA/g of MMT (-29± .7 mV), 5.8 mg of PA/g of MMT (-27.3±0.4 mV) 





4.2.5 Solid-state Characterization 
The solid states of the API-MMT nanocomposites were studied via PXRD and DSC. Figure 
4.8 shows the PXRD patterns of the three ‘as received’ APIs and the related API-MMT 
nanocomposites. As received clozapine, recrystallized curcumin and as received 
carbamazepine show characteristic high-intensity diffraction peaks, as do the diffractograms 
for 23%, 21.8% and 33.3% w/w physical mixtures of CLO-MMT, CUR-MMT and CBMZ-
MMT respectively; the physical mixtures were prepared by mixing the required amount of as 
received API and MMT by spatula. No trace of the typical crystalline peaks of clozapine and 
curcumin were observed for the CLO-MMT and CUR-MMT nanocomposites respectively 
indicating the X-ray amorphous nature of the clozapine and curcumin nanoparticles. In the case 
of CBMZ-MMT nanocomposites, the PXRD showed peaks corresponding to Form III 
carbamazepine when the loading was increased to 33.3 % w/w (Figure 4.8 (c)). However, the 
intensity of the peaks was somewhat less than that of the corresponding CBMZ-MMT physical 
mixture with an equivalent composition, likely indicating a considerable degree of amorphous 
component in the CBMZ-MMT nanocomposite. 
Additionally, DSC was used to further confirm the solid form of the curcumin, clozapine and 
carbamazepine nanoparticles adsorbed onto the MMT carrier particles. The DSC patterns of as 
received curcumin and clozapine (Figure 4.9) showed a sharp endothermic peak at 181.6±0.2 
and 193.05±0.5 ⁰C respectively corresponding to their melting temperatures. In the case of as 
received carbamazepine, an endothermic peak was observed at 176.4±0.5 ⁰C which indicates 
the melting of Form III which spontaneously recrystallized to Form I indicated by an 
exothermic peak at 177.6±0.3 ⁰C 180. A sharp endothermic peak was then observed at 193±0.2 
⁰C, which indicates the melting of Form I in agreement with literature reports180.  
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The physical mixtures of 23%, 21.8% and 33.3% w/w clozapine, curcumin and carbamazepine 
respectively with MMT showed similar thermograms to their as received and recrystallized 
forms. However, no melting peak for clozapine or curcumin was observed for the CLO-MMT 
or CUR-MMT nanocomposites with 23%, and 21.8% w/w loadings respectively, pointing to 
an amorphous state of the clozapine and curcumin nanoparticles within these nanocomposites 
(Figure 4.9 (a) and (b)). An endothermic peak corresponding to the melting of carbamazepine 
Form III was observed for the CBMZ-MMT nanocomposite when the loading was increased 
to 33.3% w/w, but with a much lower peak area than that observed for the 33.3% w/w physical 
mixture of CBMZ and MMT (Figure 4.9 (c)). Thus all the DSC measurements are in good 
agreement with the PXRD measurements. No difference in PXRD and DSC data were observed 
















Figure 4.8: PXRD patterns of (a) as received clozapine (CLO), MMT, a 23% w/w physical 
mixture of clozapine and MMT, and clozapine nanoparticle-MMT nanocomposites at different 
loadings of clozapine (% w/w); (b) recrystallised curcumin (CUR), MMT, a 21.8% w/w 
physical mixture of curcumin and MMT, and curcumin nanoparticle-MMT nanocomposites at 
different loadings of curcumin (% w/w); and (c) as received carbamazepine (CBMZ), MMT, a 
33.3% w/w physical mixture of carbamazepine and MMT, and carbamazepine nanoparticle-














Figure 4.9. DSC profiles of (a) as received clozapine (CLO), MMT, a 23% w/w physical 
mixture of clozapine and MMT and clozapine nanoparticle-MMT nanocomposites at different 
loadings of clozapine (% w/w); (b) recrystallised curcumin (CUR), MMT, a 21.8% physical 
mixture of curcumin and MMT and curcumin nanoparticle-MMT nanocomposites at different 
loadings of curcumin (% w/w); and (c) as received carbamazepine (CBMZ), MMT, a 33.3% 
physical mixture of carbamazepine and MMT and carbamazepine nanoparticle-MMT 









Nanoparticles of three poorly water-soluble APIs (namely CLO, CUR and CBMZ) were 
produced via reverse liquid antisolvent precipitation and promptly stabilised in situ by 
adsorption onto bare (that is, unfunctionalised) MMT clay particles, affording API-MMT 
nanocomposite solids that were easily isolatable via vacuum filtration. This approach was used 
successfully to produce API-MMT nanocomposite solids with various API loadings (% w/w). 
Solid state characterisation of the isolated nanocomposite solids via PXRD and DSC supports 
the view that the APIs were predominantly present in amorphous forms. The API dissolution 
profiles for these nanocomposite solids (at various API loadings) were considerably better than 
the corresponding profiles for the respective crystalline APIs in terms of the rate of API 
dissolved. Furthermore, CBMZ-MMT nanocomposite solids up to API loadings of 33.3% w/w 
displayed dissolution profiles comparable with that of a polymer-stabilised nanosuspension of 
CBMZ (30 nm particle size); and CUR-MMT and CLO-MMT nanocomposite solids at API 
loadings of 9% and 6.5% w/w respectively displayed dissolution profiles that approached those 
of polymer-stabilised nanosuspensions of CUR (173 nm particle size) and CLO (27 nm particle 
size) respectively. When combined with the abovementioned PXRD and DSC findings, the 
comparable nature of the dissolution profiles for these API-MMT nanocomposite solids and 
their respective polymer-stabilised nanosuspensions implies that the particle sizes of the APIs 
in the CUR-MMT (9% w/w loading), CLO-MMT (6.5% w/w loading) and CBMZ-MMT (33% 
w/w loading) nanocomposite solids are similar to the nanoparticle sizes of CUR, CLO and 
CBMZ in their respective nanosuspension. As such, the authors contend that reverse liquid 
antisolvent API precipitation in the presence of MMT (acting as an in situ solid adsorbent 
stabiliser) offers a robust and straightforward means of generating readily isolatable API-MMT 
nanocomposite solids.  
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However, when the CLO and CUR loading on MMT was increased to 23% and 21.8% 
respectively, the dissolution profiles deteriorated. The poorer dissolution behavior of CLO and 
CUR at these higher loadings is consistent with aggregation of the API nanoparticles on the 
MMT surface, since these nanoparticle aggregates would have less available surface area for 
dissolution. Therefore, in order to improve the dissolution profiles of CUR and CLO at higher 
loadings, the surface charge of MMT was modified by the adsorption of a cationic protein 
protamine (PA) prior to the antisolvent precipitation step to produce CUR-PA-MMT and CLO-
PA-MMT nanocomposite solids. The addition of protamine extends the range of loadings of 
CLO and CUR at which fast (that is, nanosuspension-like) dissolution profiles are maintained. 
4.2 mg of PA/g of MMT was found to be the optimum PA coverage at which nanosuspension-
like dissolution profiles were preserved for CUR-PA-MMT and CLO-PA-MMT at 21.8% and 
23% API loadings respectively.  
CLO and CUR likely attach to MMT’s negatively-charged surface via 
hydrophobic/electrostatic interactions. It is hypothesized here that modifying this surface with 
positively-charged PA increases the availability of more favourable adsorption sites for the 
attachment of negatively charged CLO and CUR nanoparticles. Therefore, the overall increase 
in available adsorption sites on the MMT surface allows a more homogenous, segregated 
dispersion of negatively-charged API nanoparticles to adsorb onto the functionalized MMT 
carrier, thus facilitating the observed preservation of nanosuspension-like dissolution profiles 
at the higher API loadings. The zeta potentials of CLO and CUR nanoparticles are -28.5 ±2.5 
and -33±1.5 mV respectively. Interestingly, their dissolution behaviour from MMT is 
comparable with previous findings from our group where API nanoparticles with zeta 
potentials in the range of -30 to -40 mV only displayed enhanced dissolution profiles at higher 
API loadings when PA surface coverages of 3 to 5 mg/g MMT were used 164,241. 
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In a separate study, nanoparticles of dalcetrapib (DCP)240 were isolated onto MMT up to 20.9% 
w/w but PA was not required to preserve an API dissolution profile comparable with that of 
the DCP nanosuspension240. Indeed, modifying MMT’s surface with PA made no meaningful 
improvement to the DCP’s dissolution profile from the resulting nanocomposites. This is 
similar to the findings reported here for CBMZ. CBMZ and DCP nanoparticles have similar 
zeta potentials: -13±1.5 and -14±2.5 mV respectively. As such, the zeta potential of the API 
appears to have a significant influence on the maximum API loading that can be achieved on 
MMT while still preserving the dissolution profile of polymer stabilized nanoparticles. When 
the zeta potential of the API nanoparticles is more negative than about -25 mV  (for example, 
in the cases of fenofibrate (-25.3 ± 0.9 mV)164, valsartan (-42.5 ± 1.4 mV, chapter 3), clozapine 
(-28.5 ± 2.5 mV) and curcumin (-33 ± 1.5 mV)) (Table 4.1) the dissolution properties of the 
corresponding API nanocomposites deteriorate at API loadings above about 10% w/w  (except 
for valsartan’s nanocomposites whose dissolution properties deteriorated above 20% w/w). For 
these APIs, protamine functionalization of MMT extends the loading ranges where 
nanosuspension-like dissolution profiles are preserved to 25 to 30% w/w. Table 4.1 shows the 
maximum achievable API loadings on MMT and PA-MMT that preserved nanosuspension-
like dissolution profiles. These data suggest that in order to achieve nanosuspension-like 
dissolution profiles for higher-loaded API nanocomposites, it is only necessary to functionalise 
the MMT with PA when the zeta potential of the API particles is more negative than ca. -25 




Figure 4.10.  The influence of PA’s presence () and absence () on the initial dissolution 
rates of API nanoparticles with different zeta potentials from their respective API 
nanocomposites at the following maximum achieved API loadings (% w/w): Val (33.3%), CUR 
(21.8%), CLO (23%), FF (9%), CBMZ (33.3 %) and DCP (20.9 %).  
Thus optimizing the balance between the zeta potentials of API nanoparticles and MMT carrier 
particles is seen as an important factor in preserving the nanosuspension-like dissolution 








Table 4.1. Zeta potential measurements and particle sizes* for the nanoparticles of six APIs 
produced via antisolvent precipitation,  and the corresponding maximum API loadings on 
MMT and PA-MMT at which nanosuspension-like dissolution profiles are preserved. 






































-25.3 ± 0.9 200-300 4.8 9 4.6 
Clozapine 
(CLO) 
-28 ± 2.5 27±0.5 6.5 23 4.2 
Curcumin 
(CUR) 
-33 ± 1.5 173±0.8 9 21.8 4.2 
Valsartan 
(VAL) 
-42.5 ± 1.4 50±0.4 20 33.3 3 
Dalcetrapib240 
(DCP) 
-14 ± 2.5 429±51 20.9 20.9 0 
Carbamazepine 
(CBMZ) 
-13 ± 1.5 30±0.5 33.3 33.3 0 







In conclusion, nanoparticles of clozapine (27 nm), curcumin (173 nm) and carbamazepine (30 
nm) with zeta potential -28.5±2.5, -33±1.5 and -13±1.5 mV respectively were successfully 
stabilized and isolated onto montmorillonite (MMT) carrier particles. Nanosuspension-like 
dissolution profiles were preserved for these APIs from the resulting nanocomposite solids up 
to API loadings of 23%, 21.8% and 33.3% w/w respectively, although prior functionalisation 
of MMT’s surface with protamine (PA) was necessary to achieve this in the cases of clozapine 
and curcumin. As such, the dissolution profiles of these nanoparticles from their respective 
MMT / PA-MMT nanocomposites were shown to be influenced by parameters such as the zeta 
potential of the API nanoparticles, the degree of PA functionalization and the API loading on 
the carrier particle system. API nanoparticles with zeta potentials more negative than ca. –25 
mV required the MMT surface to be functionalised with PA in order to preserve 
nanosuspension-like dissolution profiles at higher API loadings; when so required, the optimal 
PA loading was consistently around 4 mg/g of MMT. PA likely limited API nanoparticle 
aggregation by improving MMT’s adsorptive characteristics and thus facilitated the enhanced 
dissolution profiles of these API nanoparticles at higher loadings from the dried state. By 
contrast, API nanoparticles with zeta potentials less negative than ca. –25 mV did not require 
the MMT modification with PA in order to maintain enhanced dissolution profiles at high API 
loadings.   
This method of carrier particle mediated stabilization and isolation of API nanoparticles 
offers a potentially viable means of producing a fast dissolving, solid dosage form for poorly 
water-soluble APIs, where the surface properties of the carrier particle can be effectively 
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Producing drug nanoparticles via the “bottom up” technique of antisolvent precipitation is 
challenging to scale-up in batch mode due to variations in local supersaturation and thus a wide 
particle size distribution within the larger batch processing volume. Another major challenge 
is the subsequent isolation of the nanoparticles via conventional techniques such as spray 
drying, freeze-drying or centrifugation, which induce particle agglomeration due to the high 
surface energy of the nanoparticles. This work investigated the technical feasibility of 
preparing, stabilizing and isolating poorly water-soluble drug nanoparticles via a small-scale 
antisolvent precipitation process operating in continuous mode. Specifically, a novel 
continuous process was demonstrated for the carrier particle mediated production, stabilization 
and isolation of valsartan nanoparticles into a solid form using montmorillonite clay particles 
as the carrier. The continuous process operated robustly for the full duration of the experiment 
(~16 min) and steady-state conditions were reached after ~5 min. Nanoparticles of valsartan 
(51±1 nm) were successfully prepared, stabilized  and isolated with the help of montmorillonite 
(MMT) or protamine functionalized montmorillonite (PA-MMT)  into the dried form by this 
continuous route. The dissolution profile of the isolated valsartan nanocomposite solids was 
similar to that of valsartan nanocomposite solids produced via the corresponding laboratory 
scale batch mode process, which confirms that the product quality of the valsartan 
nanocomposite solids (principally their nanoscale particle size and solid-state form) are 
retained during the continuous processing mode. Furthermore, tablets produced via direct 
compression of the isolated valsartan nanocomposite solids displayed a dissolution profile 
comparable with that of the powdered nanocomposite material. PXRD, DSC, SSNMR and 
dissolution studies indicate that the valsartan nanoparticles produced via this continuous 
process were amorphous  and exhibited a shelf-life stability of  >10 months, thus indicating the 
139 
 
long-term stability potential of valsartan nanocomposites produced via this carrier particle 
mediated continuous antisolvent precipitation, stabilisation and isolation process.                                         
5.1. Introduction 
Pharmaceutical crystallization is typically carried out in batch reactors using cooling, normal 
and reverse antisolvent addition, evaporation, pH adjustment or chemical reaction to generate 
supersaturated solutions that induce solute molecules to come together to nucleate and grow  
into crystals242,243. However, in recent years, there has been increased industrial and academic 
interest in changing pharmaceutical processing from batch to more efficient continuous 
processes244–249. Continuous manufacturing provides several potential opportunities, such as 
better control of product quality, lower costs, greater reliability and safety, better sustainability 
and increased flexibility in manufacturing250–252. Although batch operation is the most common 
and well-understood approach, there are still significant issues associated with it, such as batch 
to batch variability, difficulty in scaling up and producing homogeneous processing conditions, 
which can lead to substantial issues in downstream processes, subsequent formulation into 
medicines and in vivo performance242,252–254. Continuous manufacturing has inherent 
advantages over batch with respect to process control. The steady-state is usually easier to 
control due to tighter equipment integration as well as a higher level of automation245,255–258.  
Drug nanoparticles at an industrial scale are mainly produced by “top-down” techniques such 
as milling and high-pressure homogenization, which basically break down large crystalline 
drug particles into nanoparticles79,259. In contrast, “bottom-up” techniques, which are based on 
controlled precipitation/crystallization to form nanoparticles by building up particles from the 
molecular state, are rarely used at the industrial scale260,261. One such bottom-up technique, 
liquid antisolvent precipitation, is a fast, simple and cost-efficient method of nanoparticle 
production. It involves the rapidly mixing a solution of drug in solvent with a solvent-miscible 
antisolvent; this generates a high supersaturation that induces a fast nucleation rate, leading to 
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the production of nanoparticles. However, it has the inherent problem of scale-up in batch mode 
due to the challenge of generating a uniformly high supersaturation throughout the large batch 
volume. The resulting variation of supersaturation throughout the process volume leads to 
variations in precipitation kinetics, which in turn can influence the final particle size 
distribution and quality of the product252,258. However, performing antisolvent precipitation in 
continuous mode offers the potential to overcome this problem because the process can be 
designed to run using volumes small enough to limit the non-uniformity of supersaturation 
levels. Thus, drug nanoparticle production via continuous antisolvent precipitation not only 
offers the possibility of process intensification but also offers better control over particle size 
distribution relative to batch processing106,262. As such, there is potential to transform current 
industrial practice by producing drug nanoparticles using continuous antisolvent precipitation.  
A thorough search of the pharmaceutical literature for the production of drug nanoparticles via 
antisolvent precipitation shows that the majority of experimental data were obtained in batch 
mode44,169. Very few reports describe the production of nanoparticles via continuous 
antisolvent precipitation, and of these the drug nanoparticles were often isolated from 
suspension into the solid-state via coupling the continuous process with spray 
drying169,259,260,263. However, isolating nanoparticles into the solid-state using complex 
techniques such as spray drying (and also freeze-drying) can induce agglomeration of the 
nanoparticles due to their high surface energy52,264. This study, therefore, focussed on 
developing a continuous antisolvent precipitation process for the production and stabilization 
of drug nanoparticles into the solid-state with the help of montmorillonite (MMT) clay carrier 
particles, and their subsequent isolation via simple filtration. 
Chapters 3 & 4 described a highly effective way to prepare, stabilise and isolate nanoparticles 
of a range of poorly water-soluble APIs via a reverse antisolvent precipitation method in a 
batch mode. Indeed, a good understanding of the batch process is almost always required to 
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make a successful design of continuous processes249. The objective of this work was to develop 
a continuous antisolvent precipitation process for the preparation, stabilization and isolation of 
poorly water-soluble drugs with the help of clay carrier particles by an in-house developed 
continuous system. These clay carrier particles served the dual purpose of stabilizing the 
nanoparticles in suspension and allowing for their isolation via simple filtration. The process 
performance was characterized in terms of mixing and total residence times. The product 
quality was characterized in terms of the particle size distribution of nanosuspension, 
percentage isolation, solid-state form, stability of isolated product and dissolution rate by 
comparing them with batch formulations. The model compound chosen for this study was 
valsartan (Val), as it was observed in the previous study (Chapter 3) that Val nanoparticles 
exhibit good stability when precipitated in batch mode with the help of soluble stabilizers or 
carrier particles. The aim of this study, therefore, was to determine whether Val nanoparticles 
of similar product quality can be prepared, stabilized and isolated in a continuous process. 
Process variables of antisolvent precipitation such as antisolvent/solvent ratio (was maintained 
same as that of batch process), flow rate of antisolvent containing Pluronic F-127 and drug 
solution in solvent (ranged from 28 ml/min to 50 ml/min- antisolvent, 0.66 ml/min to 1.13 
ml/min- solvent), residence time (ranged from 1-2 min) and flow rate of suspended carrier 









5.2. Results and discussion 
5.2.1 Steady-state measurement 
At the studied flow-rates, one nominal complete ‘residence time’ of the precipitation chamber 
(i.e. 60 mL) took 1.17 minutes to collect as a discrete aliquot, as discussed in section 2.2.3.1. 
Also, the maximum attainable concentration of valsartan in the precipitation chamber (i.e. 
assuming all available valsartan had precipitated as it passed through the precipitation 
chamber) was 2.21 mg/mL. As such, steady state conditions were deemed achieved once the 
valsartan concentration had reached 2.21 mg/mL in the precipitation chamber mixture and had 
thereafter remained at a constant value, from one discrete collected aliquot to the next. On this 
basis, the system was found to achieve steady state operation after four ‘residence times’, which 
equated to the collection of four aliquots over ca. 5 min (4 residence times  1.17 min / 
residence time). Thereafter the continuous system operated robustly for the entire duration of 





Figure 5.1. The concentration of valsartan (mg/mL) in each of the aliquots collected in series. 
Each aliquot volume corresponds to one residence time of the precipitation chamber (i.e. 60 
mL), and the maximum attainable concentration of valsartan is 2.21 mg/mL based on the flow 
rates of the solvent (valsartan solution) and antisolvent (aqueous solution of Pluronic F-127). 
At these flow rates, ~3 L of nanosuspension can be produced per hour, and while the single-
injection system available used here limited the duration of the experiment, a parallel syringe 







5.2.2 Particle size distribution of polymer stabilized nanosuspensions from the continuous 
preparation 
Rapid mixing during antisolvent precipitation is necessary to generate smaller particle size 
distributions44. The steady-state particle size distribution of valsartan nanoparticles stabilized 
by Pluronic F 127 changes from 68 ± 7 nm to 51± 1 nm as the stirring speed increased from 
800 to 1200 rpm in the precipitation chamber, Figure 5.2. Thus rapid mixing appears to 
generate a more homogeneous solution, with a uniformly high supersaturation, which results 
in faster nucleation rates generating smaller particle sizes. 
The particle size distribution at 800 rpm was not as narrow as that obtained during the batch 
experiment in which the particle size of 50 ± 0.4 nm was obtained with very narrow particle 
size distribution at 800 rpm (chapter 3, section 3.2). However, when the stirring was increased 
to 1200 rpm, the particle size distribution obtained during the continuous process is similar to 
the batch particle size distribution at 800 rpm, Figure 5.2. This can be attributed to the different 
level of mixing that is required when comparing the batch experiment with the continuous. All 





Figure 5.2. Particle size distributions of valsartan nanosuspensions at steady state (i.e. after 
the 4th residence time) following reverse antisolvent precipitation in continuous mode in the 
presence of Pluronic F 127 at stirring speeds of 800 and 1200 rpm. 
5.2.3 Attachment of valsartan nanoparticles onto MMT / PA-MMT carrier particles 
during the continuous process  
 In the previous study (Chapter 3, section 3.2.2), almost complete adsorption (> 99%) of 
valsartan nanoparticles onto MMT or PA-MMT carrier particles was observed using the batch 
process. The attachment of Val nanoparticles onto MMT/PA-MMMT carrier particles (PA was 
used to limit the aggregation of nanoparticles onto MMT carrier particles at high valsartan 
loadings as described in chapter 3) during the continuous process was confirmed by the clear 
filtrate obtained in each aliquot as well as by checking the concentration of drug in the filtrate 
by UV-vis analysis. The concentration of API in the filtrate confirmed that almost all of the 
valsartan present had adsorbed onto the MMT/PA-MMT carrier particles (>99%). Thus it can 
be said that this continuous system is successful in preparing and isolating drug nanoparticles 
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in the solid-state insofar as >99% of the drug nanoparticles are adsorbed onto the carrier 
particles. 
5.2.4 Tabletting of Val-MMT nanocomposites 
Solid Val-MMT NC products obtained from continuous experiments were compressed to 
assess their tabletting behaviour at various Val loadings. These tablets’ tensile strength was 
observed to increase with an increase in valsartan loading in the Val-MMT NCs, which may 
be due to the good compaction properties of the API itself, Figure 5.3. A tensile strength in 
excess of 1 MPa is usually desirable for commercial tablets212. The tensile strength of all the 
tablets with different valsartan loadings exceeded this limit to form a robust tablet without any 
use of other excipients, Figure 5.3212,265. While this finding is specific to valsartan, it 
demonstrates the potential of nanocomposites produced via this continuous approach to be 
directly compressed into tablets without the need to use other excipients. 
 
Figure 5.3. Tensile strength of Val-MMT/Val-PA-MMT NCs tablets at different valsartan 
loadings (w/w) compressed at a load of 300 kg. 
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For subsequent dissolution studies, carboxymethyl cellulose (CMC) (10% w/w) was used as a 
disintegrant in tablet formulations; the addition of CMC did not affect the tensile strength of 
tablets. The tensile strength of Val-MMT/Val-PA-MMT NC tablets at different valsartan 
loadings was kept similar by compressing the 9% and 20% w/w loaded Val-MMT NCs and  
the 33.3% w/w loaded Val-PA-MMT NC (3 mg PA/g MMT) tablets at compression loads of 
300, 200 and 160 kg respectively Figure 5.4.  
 
Figure 5.4. Tensile strength of Val-MMT NC tablets at 9% and 20% w/w valsartan loadings 
and Val-PA-MMT NC tablets at 33.3% w/w valsartan loading (3 mg PA/g MMT), compacted 









5.2.5 Dissolution studies of Val-MMT/Val-PA-MMT nanocomposite powders produced 
via the continuous method 
Figure 5.5 shows the dissolution behavior of Val-MMT NC powders with 9%, 20% and 33.3% 
w/w valsartan loadings and Val-PA-MMT NC powder at 33.3% w/w valsartan loading (3 mg 
PA/g of MMT) prepared via the continuous approach. For comparative purposes, this figure 
also includes the dissolution of Val-MMT NC powders at different valsartan loading (w/w) 
(9%, 20%, 33.3% and 33.3% loading, 3 mg PA/g of MMT) prepared via the batch mode and 
Val Form E powder. The dissolution behaviors of Val-MMT NCs produced in the continuous 
method were found to be comparable with those prepared in the batch experiments and to 
dissolve much faster than the larger particle sized crystals of Form E (~11 µm), Figure 5.5. 
Thus the continuous method of preparing, stabilizing and isolating valsartan nanoparticles is 





Figure 5.5. Comparison of the dissolution profile of Val Form E (~11 µm) powder with those 
of dried Val-MMT nanocomposite powders prepared in the batch experiment and dried Val-
MMT nanocomposite powders prepared in the continuous experiment at different valsartan 
loadings: (a) 9% w/w loading, (b) 20% w/w loading, (c) 33.3 % w/w loading, and (d) 33.3% 





5.2.6 Stability of Val-MMT/Val-PA-MMT nanocomposites powders 
After storage for 2.5 months under accelerated humidity conditions, Val-MMT and Val-PA-
MMT nanocomposites displayed valsartan dissolution profiles comparable with those of 
freshly prepared Val-MMT and Val-PA-MMT nanocomposites, Figure 5.6. This supports the 
view that no recrystallization/polymorphic transformation/aggregation of the valsartan 
nanoparticles had occurred during this time. This demonstrates that the Val-MMT/Val-PA-
MMT nanocomposites produced via this continuous process possessed a shelf-life stability 
equivalent to >10 months (based on the accelerated stability storage conditions of 313 K and 
75% relative humidity for 2.5 months), thus indicating the long-term stability potential of these 
valsartan nanocomposites produced via this carrier particle mediated continuous antisolvent 















Figure 5.6. Comparison of the dissolution profile of Val Form E (~11 µm) with those of dried 
Val-MMT nanocomposites prepared in batch experiments, fresh dried Val-MMT 
nanocomposites prepared in the continuous experiment and aged Val-MMT nanocomposites 
(samples stored for 2.5 months in an accelerated humidity chamber at 313 K and 75% relative 
humidity) at different valsartan loadings (a) 9% w/w loading, (b) 20% w/w loading, (c) 33.3 





5.2.7 Dissolution studies of Val-MMT nanocomposites tablets 
The tablet (100 mg) formulation used for dissolution studies comprised a 90:10 w/w blend of 
Val-MMT or Val-PA-MMT NCs and CMC as disintegrant. The dissolution profile of valsartan 
from the tablets was found to deteriorate as the valsartan loading in the tablets increased 
(Figure 5.7). This may be due to the increase in the tensile strength of the tablets as the 































Figure 5.7. Comparison of the dissolution profile of Val Form E (~11 µm) with those for 
valsartan from the following formulations at different valsartan loadings (w/w): (a) powdered 
sample composed of a 90:10 (w/w) physical mix of Val-MMT NCs (9% w/w) and CMC, and 
Val-MMT NCs tablet (9% w/w loading, tensile strength = 1.1 mPa), (b) powdered sample 
composed of a 90:10 (w/w) physical mix of Val-MMT NCs (20% w/w) and CMC, and Val-MMT 
NCs tablet (20% w/w loading, tensile strength = 2 mPa), and (c) powdered sample composed 
of a 90:10 (w/w) physical mix of Val-PA-MMT NCs (33.3% w/w loading, 3 mg PA/g MMT) 
and CMC, and Val-PA-MMT NCs tablet (33.3% w/w loading, 3 mg PA/g MMT, tensile strength 





To minimise the effect of the tablets’ varying tensile strength on dissolution behaviour, 90:10 
w/w blends of Val-MMT or Val-PA-MMT NCs and CMC at different valsartan loadings were 
compressed to different compression loads in order to form tablets of a similar tensile strength 
(~1 mPa) for dissolution studies (as discussed in section 5.2.4). The dissolution profiles of 
valsartan from the resulting tablet formulations are comparable to those of the corresponding 
powdered physical mix samples of Val-MMT NCs and CMC as illustrated in Figure 5.8. 
Hence, the tableting of Val-MMT nanocomposites powder does not adversely affect the 
dissolution profile once the tablet compression load has been tuned accordingly to control the 
tensile strength. In principle, therefore, API-MMT nanocomposites obtained from this 
continuous process can be readily compressed into tablets without compromising the 
















Figure 5.8. Comparison of the dissolution profile of Val Form E (~11 µm) with those for 
valsartan from the following formulations at different valsartan loadings (w/w): (a) powdered 
sample composed of a 90:10 (w/w) physical mix of Val-MMT NCs (9% w/w) and CMC , and 
Val-MMT NCs tablet (9% w/w loading, tensile strength = ~ 1 mPa), (b) powdered sample 
composed of a 90:10 (w/w) physical mix of Val-MMT NCs (20% w/w) and CMC, and Val-MMT 
NCs tablet (20% loading, tensile strength = ~1 mPa), and (c) powdered sample composed of 
a 90:10 (w/w) physical mix of Val-PA-MMT NCs (33.3% w/w loading, 3 mg PA/g MMT) and 
CMC, and Val-PA-MMT NCs tablet (33.3% w/w loading, 3 mg PA/g MMT, tensile strength = 






5.2.8 Solid state characterization 
PXRD patterns were compared for Val Form E, a 33.3 % w/w physical mixture of Val Form E 
and MMT, MMT, and variously valsartan-loaded Val-MMT NCs produced via the continuous 
process (fresh samples (Figure 5.9 (a)) and samples following 2.5 months’ storage under 
accelerated humidity conditions (Figure 5.9 (b)). No characteristic valsartan diffraction peaks 
were observed in any of the variously valsartan-loaded Val-MMT nanocomposites, thus 
confirming the X-ray amorphous nature of the valsartan in the fresh samples and the samples 






























Figure 5.9. PXRD patterns for valsartan Form E (experimental and from the CSD), a 33.3% 
w/w physical mixture of valsartan and MMT, MMT, and a selection of Val-MMT 
nanocomposites with different valsartan loadings (% w/w) produced via the continuous 
process: (a) freshly produced, and (b) stored for 2.5 months under accelerated humidity 
conditions. 
DSC thermograms were compared for Val Form E, a 33.3 % w/w physical mixture of Val Form 
E and MMT, MMT, and variously valsartan-loaded Val-MMT NCs produced via the 
continuous process (fresh samples (Figure 5.10 (a)) and samples following 2.5 months’ storage 
under accelerated humidity conditions (Figure 5.10 (b)). The thermogram of valsartan Form E 
showed an endothermic peak at 138.4 ± 0.4⁰C corresponding to its melting temperature, as did 
the thermogram of its 33.3 % w/w physical mixture with MMT. However, valsartan’s melting 
peak was not detected in any of the thermograms of the variously valsartan-loaded Val-MMT 










therein were amorphous when freshly produced and did not undergo a crystalline 



































Figure 5.10. DSC thermograms for valsartan Form E, a 33.3% w/w physical mixture of 
valsartan and MMT, MMT, and a selection of Val-MMT nanocomposites with different 
valsartan loadings (% w/w) produced via the continuous process: (a) freshly produced, and 


















5.2.9 Solid-state nuclear magnetic resonance (SSNMR) of Val-MMT Nanocomposites 
Solid-state NMR (SSNMR) has established itself as a complementary technique to X-ray 
diffraction in the study of solid materials, especially in the case of APIs218–222. Indeed, contrary 
to solution NMR, SSNMR does not require the solubilization of the compounds to be analyzed, 
thus preventing the loss of any feature intimately connected with their structure in the solid-
state. It can provide precious information about poorly crystalline or even amorphous 
samples223,224. Moreover, thanks to its high sensitivity to the local environment of the observed 
nuclei, SSNMR can be employed to probe the effects of surface interactions on the materials 
of interest225,226. 
13C cross-polarization magic-angle spinning (CPMAS) spectra were acquired for crystalline 
Val Form E, freshly produced Val-MMT NCs with different valsartan loadings (16.6%, 20% 
and 33% w/w), and Val-MMT NCs following 2.5 months’ storage under accelerated humidity 
(20% and 33% w/w). This allowed evaluating the physical state of the valsartan present in the 
‘fresh’ and ‘aged’ Val-MMT nanocomposites.  





Figure 5.11. 13C (100 MHz) CPMAS spectra of Val Form E, 16.6% w/w Val-MMT NCs, 20% 
w/w Val-MMT NCs and 33% w/w Val-MMT NCs, acquired at a spinning speed of 12 kHz at 
room temperature.  
The comparison with the crystalline Val Form E shows how the signals in the spectra of the 
three Val-MMT nanocomposites are consistent with the presence of Val. The resonances in the 
three Val-MMT NCs spectra are consistently broader with respect to crystalline Val Form E, 
with an average full width at half maximum value of about 350 Hz for the Val-MMT NCs 
spectra versus about 90 Hz for Val Form E. This is due to a loss of Val’s crystallinity, 




by a comparison (not shown) between the spectra of the Val-MMMT nanocomposites and that 
of amorphous Val, reported by Skotnicki et al. in 2016266. The spectra of the three fresh Val-
MMT NCs at different Val loadings in Figure 5.11 are superimposable on each other, 
indicating that Val is not affected by significantly different interactions in the three materials 
as its loading on the MMT varies. Above the spectra in Figure 5.11, the chemical structure of 
Val is shown, with C atoms numbered to clarify the proposed assignments of the related 13C 
solid-state NMR resonances. Figure 5.12 represents a stack of the 13C CPMAS spectra of the 
two aged Val-MMT NC samples and the fresh 33% w/w loaded Val-MMT NC sample. 
 
 
Figure 5.12. 13C (100 MHz) CPMAS spectra of aged 20% w/w Val-MMT NCs, aged 33% w/w 





As in the previous figure, it is apparent how the three spectra are superimposable, suggesting 
that the 2.5 months’ storage under accelerated humidity conditions does not alter the physical 
state of valsartan in the Val-MMT nanocomposites. This confirms the excellent humidity 
stability of Val-MMT nanocomposites with an ambient shelf life equivalent to >10 months 



























An experimental study was conducted to develop a continuous and scalable process to prepare, 
stabilize and isolate valsartan nanoparticles. The reverse anti-solvent precipitation method, 
combined with isolation and stabilization of the Val nanoparticles by MMT or PA-
functionalised MMT, lends itself readily to continuous operation to achieve gram scale 
quantities of Val-MMT/Val-PA-MMT nanocomposites at a nominal reactor scale of 60 mL. 
The in-house developed continuous system operated robustly for the full duration of all 
experiments (~16 min) and steady-state conditions were reached after ~5 min. The dissolution 
profiles of the resulting Val-MMT/Val-PA-MMT nanocomposites powders were comparable 
with those of the corresponding Val-MMT/Val-PA-MMT nanocomposites produced via batch 
processing. The dissolution profiles of tablets formulated from a 90:10 w/w blend of the Val-
MMT/Val-PA-MMT nanocomposite powders with CMC (as a disintegrant) were comparable 
with those of the corresponding physical mixtures up to highest tested valsartan loading of 
33.3% w/w. According to PXRD, DSC and SSNMR data, the Val-MMT nanocomposites were 
likely to be amorphous and have a shelf life stability equivalent to >10 months based on their 
observed stability up to 2.5 months under accelerated testing conditions of  313 K and 75% 
relative humidity. Thus, the developed continuous process in this study offers a rapid and 
robust template for preparing stable API nanosuspensions, which can then be readily isolated 
via adsorption (at different API loadings) onto inert carrier particles. The resulting API-carrier 
particle nanocomposite solids are suitable for tableting, affording fast-dissolving tablets for 










In this thesis nanoparticles of a range of poorly water-soluble APIs were prepared, stabilized 
and isolated onto MMT clay carrier particles in order to enhance their dissolution rate and 
ultimately their bioavailability. The strategy taken to achieve this involved the production of 
nanoparticles in suspension using the reverse antisolvent precipitation technique in the 
presence of MMT carrier particles followed by the isolation of the resulting nanoparticle carrier 
composites into solid state by simple filtration. Achieving a high degree of supersaturation 
plays a critical role in nanoparticle formation as it promotes a fast nucleation rate (low critical 
free energy of nucleation), resulting in the formation of nanoparticles. 
To demonstrate the influence of supersaturation, Table 6.1 summarises the calculation of the 
critical free energy of nucleation for a range of supersaturations from 1.1 to 30 by applying Eq. 
1.11 (from Chapter 1, and shown again below for convenience) and taking a typical interfacial 






where γ is the interfacial energy at the solid-liquid interface, ν is the molecular volume, k is the 




              (1.11) 
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Table 6.1. The influence of supersaturation on the critical free energy of nucleation. 
Supersaturation 
(S) 
Critical free energy of 









As shown in Table 6.1, as the supersaturation increases, the critical free energy of nucleation 
(𝛥𝐺𝑐𝑟𝑖𝑡) diminishes rapidly with a ca. 300-fold decrease in the critical free energy of nucleation 
seen as the supersaturation increases from 1.1 to 5, while it decreases by around 1,300-fold as 
the supersaturation further increases to 30. Therefore, at high supersaturation the critical free 
energy of nucleation becomes very low, thus facilitating the generation of a very large number 
of nuclei leading to the formation of nanoparticles. 
The work in this thesis identified the zeta potential of the API as a crucial parameter in the 
preparation, stabilization, and isolation of poorly water-soluble API nanoparticles from 
suspension into the solid state. The zeta potential of the API influenced the dissolution 
properties from dried API-MMT nanocomposites, especially at high API loadings. Scalability 
of the above process has also been demonstrated using the novel continuous process outlined 
in Chapter 5, which yields product quality (in terms of particle size distribution and solid state 
form) identical to the product of the batch process but with higher productivity.  
The study presented in Chapter 4 devised an efficient strategy for transforming poorly water- 
soluble APIs into fast-dissolving solid dosage nanoparticle-carrier composites, whereby the 
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surface properties of the carrier particle can be tuned with prior knowledge of the zeta potential 
of the API nanoparticles to achieve optimum dissolution rates at high API loadings. Based on 
the experimental results obtained in Chapters 3 and 4, this chapter proposes a mechanism for 
the adsorption of API nanoparticles onto MMT carrier particles and for the effect of protamine 
(PA) in modifying the surface of MMT to limit the extent of nanoparticle aggregation and thus 
enhance the API’s dissolution profile at high API loadings.  
MMT has a large specific surface area (250-270 m2/g) and exhibits high adsorption, cation 
exchange capacity, and drug-carrying capabilities201,267. The surface of MMT is characterized 
by protrusions of polar hydroxyl groups (–OH) and hydrophobic siloxane groups (Si–O–
Si)207–209,268. MMT has a net negative surface charge due to (i) imperfections in the crystal 
lattice and (ii) isomorphous substitution of Si4+ by Al3+ in the tetrahedral sheet and Al3+ by 
Mg2+ in the octahedral layer201,202. The negative charges are compensated  by adsorption of 
exchangeable cations (Na+, K+, Ca2+, etc.) usually in a hydrated form (as discussed in Chapter 
2 Figure 2.10) 201,210,239,269,270. The majority of these cations are present in the interlayer; only 
a small proportion of them are located at the external surface210,239,269. Thus, the surface of 
MMT contains some positively charged potential adsorption sites due to the presence of 
exchangeable cations on the external surface or sites due to dangling hydroxyl end groups on 
the surface of  MMT. In addition the surface  contains segregated hydrophobic adsorption 
patches210,271,272. The presence of positive, negative and hydrophobic patches makes MMT 
unique and engenders it with standout adhesive ability210,267,268,271. 
Despite also being negatively charged, nanoparticles of the APIs studied in this thesis still 
adsorb onto the net negatively charged MMT carrier particles. Adsorption of the API 
nanoparticles is potentially due to the electrostatic interaction between the positively charged 
sites on the MMT clay surface and the negatively charged API nanoparticles complemented by 
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hydrophobic interactions between the APIs’ aliphatic and/or aromatic groups and the siloxane 
groups present on the MMT surface200,208,209. Due to charge repulsions, the negatively-charged 
nanoparticles would strictly avoid the negatively charged patches on the clay surface, thus 
limiting the extent of available favourable adsorption sites, Figure 6.1 (a). The extent of 
available adsorption sites on the MMT carrier particle can be approximated in terms the 
percentage covering of nanoparticles on the surface of MMT carrier particles calculated in 
Table 6.2, which shows that less than 50% of the surface area of MMT is covered by API 
nanoparticles in all cases at maximum API loading. 
Table 6.2 Summary of % coverage of Val, CLO, CUR and CBMZ nanoparticles on the surface 















per gram of 
MMT (m2 ) 
% Coverage of 
API nanoparticles 
on MMT at max. 
API loading per 
gram of MMT** 
Valsartan 
(Val) 
50 6.41015 12.5 28.5 
Clozapine 
(CLO) 
30 1.61016 11.4 26 
Curcumin 
(CUR) 
170 81013 1.8 4.2 
Carbamazepine 
(CBMZ) 
30 2.61016 18.5 42.2 
 
* 𝑁𝑜. 𝑜𝑓 𝐴𝑃𝐼 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐴𝑃𝐼 𝑢𝑠𝑒𝑑
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑜𝑛𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
  assuming spherical nanoparticles. 
**Taking the external surface area of MMT to be 44 m2/g273. 
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Here, we hypothesized that when an API nanoparticle’s charge is sufficiently negative 
(specifically, more negative than ca. -25 mV, as in cases of curcumin, clozapine and valsartan) 
and when the API loading is high enough, then ever more nanoparticles will be repelled from 
the negative regions that predominate on MMT’s surface, forcing them to agglomerate on 
MMT’s positively charged and hydrophobic surface regions instead. This will result in a loss 
of nanoparticle-induced high surface area and a consequential reduction in API dissolution 
rates Figure 6.1 (b). However, adsorption of the cationic peptide protamine (PA) onto MMT 
increases the density of positive zones on MMT’s surface. This increases the extent to which 
negatively charged API nanoparticles can attach to MMT’s surface via electrostatic interaction 
as well as faciitates the segregation of these nanoparticles due to an increase in the availability 
of more favorable adsorption sites for API nanoparticles to adsorb on MMT’s surface. As a 
result, the high surface area of nanoparticles is retained despite the higher API loadings, thus 
facilitating the enhanced dissolution profiles of these API nanoparticles from higher API 










Figure 6.1 Schematic description of the potential interactions between the API nanoparticles 
and MMT carrier particles with corresponding dissolution profiles of API nanoparticles whose 
zeta potential is more negative than ca. -25 mV (e.g. clozapine, zeta potential -28.5 ±2.5 mV): 
(a) the un-functionalized MMT onto which negatively-charged API nanoparticles would  
adsorb at the positively charged sites or the hydrophobic sites, which is sufficient for the 







(a) Low API loading  no agglomeration high nanoparticle surface 
area leading to fast dissolution 
(b)Higher API loading prior to modification of MMT with PA 
  agglomeration  lower nanoparticle surface area leading to 
poorer dissolution 
(c) Higher API loading after modification of MMT with PA 
  enhanced segregation and less agglomeration  high nanoparticle 







MMT with a high loading of API nanoparticles resulting in nanoparticles agglomeration due 
to the limited availability of suitable adsorption sites, and (c) the adequate segregation of a 
high loading of API nanoparticles on MMT’s surface  due to the increased availability of 
favourable adsorption sites following the functionalization of MMT’s surface with the cationic 
peptide, protamine (PA). 
By contrast, API nanoparticles with zeta potentials less negative than ca. –25 mV (e.g. 
carbamazepine) did not require the MMT modification with PA to maintain enhanced 
dissolution profiles at high API loadings. This may be due to less repulsive forces or smaller 
repulsive zones between nanoparticles and surface of MMT due to the presence of less negative 
charge on these APIs resulting in more favourable adsorption sites to attach with MMT. As a 
result, high surface area of nanoparticles is retained, thus facilitating the enhanced dissolution 
profiles of these higher loaded API-MMT nanocomposites without the need to modify the 























Figure 6.2 Schematic description of the potential interactions between the API nanoparticles 
and MMT carrier particles with the corresponding dissolution profiles of API nanoparticles 
whose zeta potential is less negative than ca. -25 mV (e.g. carbamazepine, zeta potential -
13±1.5 mV): (a) un-functionalized MMT with a low API loading, and (b) un-functionalized 
MMT with a high API loading. 
Optimizing the balance between the zeta potentials of API nanoparticles and MMT carrier 
particles is seen as an important factor in preserving the fast dissolution profiles for higher-
loaded API nanocomposites. The unique balance of positively charged, negatively charged and 
hydrophobic regions on its surface enables MMT to accommodate high loads of API 
nanoparticles, keeping them sufficiently dispersed from each other to allow the dissolving 







(a) Low loading of API nanoparticles that are less prone to 
being repelled  no agglomeration  high nanoparticle 
surface area leading to fast dissolution 
(b) High loading of API nanoparticles that are less prone to being 
repelled  enough segregation to avoid agglomeration  high 






nanoparticles, an additional influx of positive charge (in the form of PA) is needed to adjust 
this balance accordingly. 
The study presented in Chapter 5 developed an in-house novel continuous process for the 
preparation, stabilization, and isolation of the poorly water-soluble API valsartan with the help 
of MMT carrier particles. The product quality in terms of particle size distribution of the 
nanosuspension, dissolution rate and stability of Val-MMT nanocomposites was similar to that 
of the valsartan nanosuspension and Val-MMT nanocomposites produced via the 
corresponding laboratory-scale batch mode process, confirming that the product quality is 
retained during continuous mode processing. Furthermore, the higher productivity via this 
continuous processing generated sufficient Val-MMT nanocomposite material to fund the 
formulation of a solid state oral drug delivery system in the form of a tablets. 
Tablets require a certain mechanical strength to withstand the shocks of handling during 
manufacturing, experimental studies, packaging, shipping, and dispensing212. A tensile strength 
in excess of 1 MPa is usually desirable for tablets212. Particle size plays a crucial role in the 
tensile strength of tablets274, and tensile strength generally increases as particle size decreases 
275. Therefore, given the nanoscale dimensions of the valsartan particles in the Val-MMT 
nanocomposites, it was unsurprising to find that the tensile strength of the resulting tablets 
readily complied with the >1 MPa requirement without the need to use other excipients. 
Interestingly, the tensile strength of the tablets was observed to increase with increasing 
valsartan loading. This was probably due to an increase in cohesive interparticulate forces (such 
as mechanical interlocking, Van der Waals forces, etc.) arising from an increase in the 
nanoparticle surface area available for contact and cohesion during tableting at higher loadings 





Conclusions and Future Outlook 
 
7.1 Conclusions 
The primary goal of the study carried out in this thesis was to prepare, stabilize and isolate 
poorly water-soluble Active Pharmaceutical Ingredients (APIs) nanoparticles in solid-state 
with the help of carrier particles in a batch as well as a continuous process in order to enhance 
the dissolution rate, and hence the bioavailability of these APIs. The strategy of the project 
involved the production of these nanoparticles in suspension using a reverse antisolvent 
precipitation technique in the presence of ‘as received’ MMT carrier particles (~30 m) and/or 
MMT carrier particles whose surface had been slightly modified with a cationic protein, 
protamine sulphate salt (PA). The resulting nanoparticle carrier composites were isolated 
directly from suspension into a solid state form by simple filtration followed by air-drying. 
Nanoparticles (NPs) of four poorly water-soluble APIs, valsartan (50 nm), clozapine (27 nm), 
curcumin (170 nm), and carbamazepine (30 nm) with zeta potentials of -42.5± 2.5 -28.5 ±2.5, 
-33±1.5 and -13±1.5 mV respectively were produced, stabilised and isolated into the solid-state 
with the help of montmorillonite (MMT) / protamine modified MMT (PA-MMT) clay carrier 
particles without the need of any soluble additives. The API dissolution rates from these dried 
NP-carrier composites were comparable with those of the respective stabilized API 
nanoparticles in suspension up to maximum valsartan, clozapine, curcumin, and carbamazepine 
loadings of 33.3%, 23%, 21.8% and 33.3 % (w/w) respectively, although surface modification 
of the MMT carrier particles with the cationic protein protamine sulphate salt (PA) was needed 
for the valsartan, clozapine and curcumin NP-carrier composites in order to preserve the fast 
API nanosuspension-like dissolution rates at higher API loadings. 
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The dissolution profiles of these nanoparticles from their respective MMT/PA-MMT 
nanocomposites were shown to be influenced by parameters such as the zeta potential of the 
API nanoparticles, the degree of PA functionalization, and the API loading on the carrier 
particle system. API nanoparticles with zeta potentials more negative than ca. –25 mV required 
the MMT surface to be functionalised with PA in order to preserve nanosuspension-like 
dissolution profiles at higher API loadings. For these APIs, the optimal loading of PA on MMT 
was consistently around 4 mg/g, which appears enough to introduce a sufficient number of 
favourable adsorption sites on MMT’s surface for the homogeneous segregation of API 
nanoparticles to occur resulting in the observed nanosuspension-like dissolution profiles at 
higher API loadings. By contrast, API nanoparticles with zeta potentials less negative than ca. 
–25 mV did not require the modification of MMT with PA in order to preserve fast API 
nanosuspension-like dissolution profiles at high API loadings. This may be due to less negative 
charge on these APIs resulting in more favourable adsorption site to attach with MMT leading 
to segregation of the API nanoparticles to occur even at high API loading, without any need to 
modify the MMT’s surface with PA.  
Following the above studies on the preparation, stabilization and isolation of API nanoparticles 
in batch mode in Chapters 3 & 4, an experimental study was conducted in Chapter 5 to develop 
a continuous and scalable process to prepare, stabilize and isolate API nanoparticles in solid 
state. Specifically, a novel process of continuous carrier particle mediated stabilization and 
isolation of valsartan nanoparticles in a solid-state form using MMT as a carrier particle was 
developed. The in-house developed continuous process operated robustly for the full duration 
of the experiment (~16 min) and steady-state conditions were reached after ~5 min. 
Nanoparticles of valsartan (51±1 nm) were successfully prepared, stabilized, and isolated into 
the dried form by this continuous operation to achieve gram scale quantities of Val-MMT 
nanocomposites. The dissolution profile of the isolated valsartan nanocomposite solids was 
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similar to that of valsartan nanocomposite solids produced via the corresponding batch mode 
process (Chapter 3), confirming that the product quality (in terms of particle size distribution 
and solid state form) is retained during the continuous processing of the nanoparticles. 
Furthermore, strength of the tablets produced via direct compression of the isolated valsartan 
nanocomposite was observed to be well within the limit to form a robust tablet without any use 
of other excipients. Additionally, Val-MMT nanocomposite tablets displayed a dissolution 
profile comparable with that of the powdered nanocomposite material, thus demonstrating that 
API-MMT nanocomposites obtained from this continuous process can be easily compressed 
into tablets without compromising the dissolution behaviour of the API. 
As an overall conclusion, the studies conducted in this thesis demonstrated a method of carrier 
particle mediated stabilization and isolation of API nanoparticles which offers a potentially 
viable means of producing a fast-dissolving, solid state oral drug delivery system in the form 
of tablets for poorly water-soluble APIs. Additionally, the surface properties of the carrier 
particle can be effectively modified with prior knowledge of the API’s zeta potential in order 
to achieve high API loadings with optimum dissolution properties. Furthermore, the scalability 
of this process has been demonstrated via a continuous processing mode that is robust and 









7.2 Future Outlook 
The research conducted in this thesis demonstrated a simple and effective way for the 
preparation, stabilization and isolation of a range of poorly water-soluble APIs into solid state 
with the help of insoluble carrier particles. Drug nanoparticle production processes are often 
carried out in aqueous media containing stabilizers to ensure adequate stabilization. Often the 
nanoparticle production process is performed in conjunction with lyophilization or spray-
drying in order to reduce the risk of agglomeration and crystal growth. The study presented in 
this thesis tried to bridge the gap between the traditional production and concomitant isolation 
processes of drug nanoparticles via a simple one-step carrier particle mediated stabilization and 
isolation process. The scalability of this process was further demonstrated by transforming it 
for operation in a continuous mode. While the in-house developed continuous carrier particle 
mediated stabilization and isolation process was successful for one API, namely valsartan, a 
key area for the future work is to verify this continuous processing for a range of poorly water- 
soluble APIs. The immediate work in this regard would be the development of a continuous 
process for the APIs whose related batch formulations have already been optimized, such as 
carbamazepine, clozapine, curcumin, dalcetrapib, fenofibrate and mefenamic acid. 
Furthermore, the continuous process can be coupled with a continuous filtration and drying 
unit to make the continuous process fully automatic and more seamless, as shown in Figure 
7.1. The greater productivity of these nanocomposites via continuous processing would further 
allow tableting studies to be performed on these API-MMT nanocomposites followed by the 
related dissolution tests of the formulated tablets. 
While MMT has successfully served the dual purpose of stabilization and isolation for 
nanoparticles of every poorly water-soluble API attempted to date, a second key area for future 
work would be to further elucidate the properties of MMT that make it such an effective carrier 
particle system, as well as identifying alternative carrier particles for this technology. We have 
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Continuous filter and dryer 
established that the balance of electrostatic charges on the MMT surface plays a key role in its 
function as a carrier particle but hydrophobicity and potentially its physical layered structure 
may also play a role. Additionally, potential future work would explore ways to improve carrier 
















Figure 7.1. Schematic illustration of the coupling of the in-house developed continuous process 
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In vivo studies of nanoparticle formulations in animal models have suggested the adaptability 
of nanoparticle formulations to improve the targeting, pharmacodynamics 
and pharmacokinetics of poorly water-soluble drug candidates21,51. While we have already 
developed fast-dissolving solid-state nanoparticle composites of a variety of poorly water- 
soluble APIs, the key area for future work is to confirm the isolated nanoparticle formulations’ 
performance in animal studies in terms of bioavailability, biodistribution (tissue retention, etc.), 
toxicity and stability in the gastrointestinal (GI) tract by comparing them with control samples 
of as received API and MMT. 
 In recent years, the application of artificial intelligence (AI) techniques is rapidly growing in 
the field of biomedical science, material discovery and chemical synthesis277–279. Machine 
learning, the main component of AI has proven to solve complex issues with high efficiency. 
It has the potential to predict the success/failure of an experiment in advance thus reducing the 
extent of experimentation required and therefore accelerating drug and material design 
processes277,278. The current pharmaceutical approach of preparing, stabilizing and isolating 
drug nanoparticles is based on trial and error attempts and personal experiences, which is very 
time and resource consuming. Machine learning is a promising tool which can be applied to 
predict the process parameters, particle size, polydispersity index, stability, solvent and 
antisolvent suitabilities, suitable stabilizers, etc. Thus machine learning prediction models can 
be applied to streamline and accelerate the development of nanoparticle formulation 
technology. Experimental data including failed experiments can be used to build data-driven 
machine learning models which can reduce exploratory synthesis in the discovery of new drug 
nanoparticles. While we have already prepared, stabilized and isolated a range of poorly water-
soluble APIs, potential future work would be to build data-driven machine learning models on 
the basis of experimental data obtained from our experiments (such as process parameters, 
particle size, polydispersity index, stability, suitable solvent and antisolvent, suitable 
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stabilizers, temperature, dissolution rate, loading on carrier particles, zeta potentials, solid state 
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